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 Activation and immunoregulatory function of 
type II Natural killer T lymphocytes 
Sara Rhost 
Department of Microbiology and Immunology, Institute of Biomedicine 
Sahlgrenska Academy at University of Gothenburg 
Gothenburg, Sweden 
Natural killer T (NKT) lymphocytes make up a potent immunomodulatory 
subset of innate-like lymphocytes. NKT cells are activated by self-lipids 
presented by the unconventional MHC class I-like molecule CD1d, resulting 
in the rapid production of a range of different cytokines, that modulate innate 
and adaptive immunity. NKT cells possess regulatory properties in several 
immune setting such as autoimmunity, infection and cancer. However, the 
activation of NKT cells is not fully understood. In this thesis, we have 
addressed the role of self-lipids for type II NKT cell activation and 
autoreactivity, and employed self-lipids to investigate the immunoregulatory 
function of type II NKT cells in murine disease models.  
The glycosphingolipid (GSL) sulfatide has previously been shown to be a 
stimulatory self-ligand for type II NKT cells. Sulfatide exists naturally as a 
mixture of different isoforms and is abundant in organs such as the central 
nervous system, gastrointestinal tract, kidneys and the pancreas where it has 
important functions. We demonstrate that naturally existing isoforms, 
including C24:1 sulfatide and lyso-sulfatide, activate type II NKT cells. 
Organ specific isoforms in particular, but not non-physiological isoforms, of 
sulfatide induced efficient activation of type II NKT cells. Despite the potent 
activation of NKT cells by natural sulfatide isoforms, the autoreactivity of the 
type II NKT cells to CD1d-expressing cells was not dependent on sulfatide 
production by the stimulatory cells, demonstrating that other self-lipids were 
causing autoreactivity. In a search for such lipids, isolated from stimulatory 
cells, we identified two novel NKT cell activating self-GSLs, β-
glucosylceramide and β-galactosylceramide and defined their stimulatory 
isoforms. However, by using antigen presenting cells deficient in all GSLs 
we could demonstrate that the autoreactivity of the type II NKT cells did not 
require GSLs. In summary, we demonstrate that natural isoforms of sulfatide, 
β-glucosylceramide and β-galactosylceramide are ligands for type II NKT 
cells, suggesting that they may play a role to activate type II NKT cells upon 
increased exposure in autoimmunity or tumor immunity. We also find that 
the CD1d-dependent natural autoreactivity of the type II NKT cells depends 
on lipids other than GSLs.  
Sulfatide is present in pancreatic β-cells that are targets for autoimmune 
destruction in type I diabetes (T1D). We demonstrate immune reactivity to 
sulfatide in non-obese diabetic mice that spontaneously develop TID. 
However, treatment of these mice with sulfatide, to activate 
immunomodulatory type II NKT cells, did not confer protection from TID. In 
contrast, we found that sulfatide treatment significantly improved the survival 
rate of mice with Staphylococcus aureus sepsis. The protective effects 
mediated by sulfatide required CD1d but not type I NKT cells, suggesting 
that activated type II NKT cells ameliorated sepsis development. Protection 
was associated with reduced serum levels of pro-inflammatory cytokines and 
improved platelet counts.  
In conclusion, our results provide novel information on the activation of type 
II NKT cells, and expands our understanding of their immunomodulatory 
capacity to improve disease outcome.  
Keywords: NKT cells, GSL, Activation, T1D, S. aureus sepsis 
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 POPULÄRVETENSKAPLIG 
SAMMANFATTNING  
Immunförsvarets viktiga uppgift är att skydda oss mot invaderande 
mikroorganismer. Immunförsvaret är uppbyggt av immunceller vars roll är 
att urskilja det som är främmande, samtidigt som de skall vara toleranta mot 
kroppens egna vävnader. Detta innefattar ett enormt komplext system som i 
stora drag består av två delar, det medfödda immunsystemet och det adaptiva 
immunförsvaret. Det medfödda immunförsvaret har till uppgift att snabbt 
skydda oss mot hotande mikroorganismer, vilket resulterar i ett mindre 
energikrävande system som saknar specificitet och immunologiskt minne. 
Däremot, aktivering av det adaptiva immunförsvaret medför nästintill oändlig 
specificitet och skapar dessutom ett minne som skyddar mot senare 
infektioner av samma sort. För att särskilja mellan egna och främmande 
substanser så finns det regulatoriska celler. Dessa celler kan reglera 
immunförsvaret så att vi inte skapar ett immunförsvar mot kroppsegna eller 
ofarliga främmande substanser. Det finns dessutom celler som fungerar som 
en länk mellan det medfödda och det adaptiva immunförsvaret. Dessa celler 
aktiveras snabbt och medverkar i att forma det adaptiva immunförsvaret.  
Utformningen av det adaptiva immunförsvaret medför en risk att utveckla 
celler som känner igen och attackerar kroppsegna substanser. Detta kan leda 
till utveckling av autoimmuna sjukdomar, så som typ I diabetes eller multiple 
scleros (MS). Naturliga mördar T celler är exempel på celler som fungerar 
som en länk mellan det medfödda och det adaptiva immunförsvaret. Dessa 
celler genomgår en unik mognadsprocess i brässen som innebär att de 
selekteras av kroppsegna lipider och blir autoreaktiva. Det medför att de som 
mogna celler snabbt kan aktiveras och därmed kan de medverka till att styra 
det adaptiva immunförsvaret. Studier har visat att de naturliga mördar T 
cellerna medverkar i regleringen av flera autoimmuna sjukdomar, och kan 
stärka immunsvaret mot infektioner och cancer. Exakt hur dessa celler 
aktiveras är idag okänt.  
Här visar vi att en typ av naturliga mördar T celler (typ II) aktiveras av olika 
former av den kroppsegna lipiden sulfatid. Sulfatid tillhör en grupp av lipider 
kallade glykosfingolipider och finns i organ såsom centrala nervsystemet och 
bukspottkörteln, där sulfatid underlättar vid nervsignalering, respektive 
medverkar vid frigörandet av insulin. Vi visar att naturliga mördar T celler 
aktiveras av organspecifika isoformer av sulfatid men att den naturliga 
autoreaktiviteten inte beror på sulfatid. För att undersöka vilka lipider som 
medverkar i autoreaktiviteten så analyserade vi lipider från celler som ger 
upphov till stark naturlig aktivering av naturliga mördar T celler. Från den 
studien hittade vi ytterligare två glykosfingolipider som gav upphov till 
naturliga mördar T cellers aktivering, nämligen galaktosylceramid och 
glucosylceramid. Vidare fann vi att lipider från glykosfingolipid gruppen inte 
var nödvändiga för uppkomst av autoreaktivitet av naturliga mördar T celler, 
vilket betyder att kroppsegna lipider involverade i autoreaktiviteten av typ II 
naturliga mördar T celler måste vara av en annan sort. Vi visar även i en 
djurmodell att behandling med glykosfingolipiden sulfatid leder till 
aktivering av typ II naturliga mördar T celler som dämpar immunförsvaret 
vid akut blodförgiftning vid allvarlig bakterie infektion, så kallad septisk 
chock, utlöst av systemisk närvaro av Staphylococcus Aureus bakterien. 
Sulfatid behandling medförde en minde akut inflammationsprocess och till 
följd av det så förbättrades blodflödet något, och även koagulationsprocessen. 
I en djurmodell för typ I diabetes så medförde behandling med sulfatid inga 
effekter på utvecklingen av sjukdomen.  
Sammanfattningsvis så har vi medverkat i att brädda kunskapen om hur 
naturliga mördar T celler aktiveras och hur man kan manipulera 
immunsystemet och motverka sepsis vid akut systemisk bakterieinfektion, 
genom att aktivera just naturliga mördar T celler.  
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Introduction 
1 
INTRODUCTION 
General introduction 
We are constantly exposed to infectious agents, but in spite of that, most of 
the time our immune system is able to fight off these infections. The first line 
of defense against pathogens occurs through mechanical barriers such as the 
epithelial layer, as well as through different chemical substances. A break 
through this barrier by harmful pathogens leads to the activation of the innate 
immune system, resulting in inflammation. Following activation of the innate 
immune system and subsequent inflammation, activation of the adaptive 
immunity takes place [1]. The adaptive immunity involves populations of 
cells with tremendous diversity in antigen recognition due to somatic 
rearrangement of genes that generates highly specific receptors [2]. This is in 
contrast to innate immune cells that are activated by pathogen associated 
molecular patterns on pathogens, so called PAMPs, through recognition by 
non-rearranged receptors [3]. Activation of the adaptive immunity will 
develop into memory against the specific pathogen, resulting in protection 
against infection upon re-exposure to the same pathogen. In contrast, the 
innate immune system does not form any specific memory. Although these 
two systems have distinct functions, interplay between them is important to 
establish an efficient protection against harmful pathogens as well as to create 
a good immunological memory.  
To facilitate the link between the innate and the adaptive immune response, 
there are cells that possess features of both innate and adaptive immunity [4-
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and liver, rather then in blood or secondary lyphoid structures such as lymph 
nodes and spleen, which are the main site for adaptive lymphocytes. This 
results in an effective first line of defense against pathogens and a 
complement to innate immunity for further activation of immune cells in the 
adaptive immunity. The activated memory phenotype of innate-like 
lymphocytes is crucial for their immediate response and it indicate prior 
exposure to self antigen [4]. The innate-like lymphocytes include natural 
killer T (NKT) cells, γδ T cells, CD8αα T cells, marginal zone B cells 
(MZB) and B1-B cells. In this thesis, the activation and immunoregulatory 
ability of NKT cells have been studied.  
Hybrids of innate and adaptive immune cells 
– “innate-like lymphocytes”  
A hallmark of the innate-like lymphocytes is the recurrent expression of 
receptors with similar specificity. This is found for both B cell receptors 
(BCR) and T cell receptors (TCR) that recognize common molecular 
structures from pathogens as well as self antigens. In contrast to conventional 
lymphocytes, which are part of the adaptive immune response, activation of 
innate-like lymphocytes leads to rapid expression of effector functions. In 
terms of NKT cells, they are a major source of a range of different cytokines 
of both T helper (Th) 1 and Th2 type. Many innate-like T lymphocytes are 
restriced by non-classical major histocompatibility complex (MHC) class I 
molecules. The MHC class I-like molecule CD1d represents one of these 
unconventional MHC class I complexes. Development of functional NKT 
cells requires CD1d expression in the thymus [5, 6].  
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CD1 molecules 
CD1d and other isoforms of CD1 
MHC class I like CD1 molecules are a lineage of antigen presenting proteins 
that have evolved to present lipid antigens to T cells [7]. The CD1 genes 
encode non-polymorphic proteins that associate with β2-microglobulin (β2m) 
[8]. Five CD1 molecules have been identified in humans, CD1a-e [9-12]. 
They are divided into three groups according to their sequence similarities in 
α1 and α2 domains, where CD1a-c make up group 1, CD1d group 2 and 
CD1e is an intermediate and separated in group 3. In humans, group 1 CD1 
molecules present lipid antigens to clonally diverse T cells that mediate 
immunity to microbial lipid antigens. By contrast, CD1d molecules present 
lipid antigens to NKT cells (reviewed in [13]). In mice, CD1d is the only 
CD1 molecule expressed. Similar to MHCI, the α-chain of CD1d folds into 
three domains, α1, α2 and α3, which associate with β2m [14]. The antigen 
binding groove of CD1d consists of two large hydrophobic pockets, A´ and 
F´. The binding groove is closed at both ends but is accessible at the top of 
the molecule though a narrow opening [15]. CD1d binds lipids of various 
structures, such as glycosphingolipids (GSLs) [16, 17] and phospholipids 
[18]. Further, a binding capacity of non-lipid molecules has also been 
documented [19]. 
CD1d expressing cells 
In mice, CD1d is mainly found on professional antigen presenting cells 
(APC) such as dendritic cells (DCs), macrophages and B cells [20-23]. 
Among those APCs, DCs are the most potent APCs in stimulating NKT cells 
by ligand [24]. Localization of CD1d to the endocytic system in these 
monocyte derived DCs was observed, which suggests a possible mechanism 
for achieving efficient antigen loading onto CD1d. Interestingly, splenic 
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marginal zone (MZ) B cells display the highest CD1d expression among B 
cells in mice [21]. MZ B cells belong to the innate-like lymphocytes and 
localize in the MZ of the spleen. The MZ is positioned at the interface 
between the non-lymphoid red pulp and the lymphoid white pulp. In MZ, 
specialized APCs capture foreign antigens circulating in blood for further 
activation of the immune system. NKT cells interact productively with B 
cells. Leadbetter and colleagues show that when using haptenated lipid 
antigen for type I NKT cells, type I NKT cells localized to the B cell area and 
provided cognate help for class-switched antibody responses [25, 26]. 
Further, consistent with their higher level of CD1d, MZ B cells induced more 
proliferation of type I NKT cells than follicular B cells, suggesting that MZ B 
cells are efficient at activating type I NKT cells. Further, in liver, sinusoid-
lining endothelial cells express high levels of CD1d, while Kupffer and DC 
have somewhat lover levels. This suggests that in liver, where NKT cells are 
highly abundant, they are constantly surrounded by CD1d expressing cells 
[27]. During chronic viral hepatitis infection, CD1d expression on hepatic 
APCs increases in parallel with the progression of inflammation and 
subsequent tissue damage [28], suggesting an increased interaction between 
hepatic APCs and NKT cells. In the central nervous system (CNS), CD1d is 
expressed on microglia cells, and during inflammation, their expression of 
CD1d increases significantly [29]. Accumulation of NKT cells has been 
observed in CNS during an ongoing inflammatory response [30], indicating 
that NKT cells may interact with CD1d on microglia. Importantly, CD1d is 
also expressed on CD4+CD8+, double positive (DP) thymocytes [31], which 
is indispensable for NKT cell development. The role of CD1d expressing DP 
thymocytes will be discussed later in this thesis. The outcome of NKT cell 
stimulation will depend on which of these APCs that interacts with the NKT 
cell, and moreover, the activation state of the APC will influence its capacity 
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to activate NKT cells, through modulation of CD1d expression and through 
other mechanisms.  
Pathways of antigen processing and presentation 
on CD1d 
The CD1d molecule is similar in structure to that of MHC class I, with a 
transmembrane heavy chain with three α-domains, non-covalently attached 
to β2m [13, 32]. Upon synthesis, the heavy chain of CD1d is translocated into 
the endoplasmic reticulum (ER) where N-linked glycans are attached and 
association with β2m and self-lipids takes place [8]. Following assembly in 
ER, CD1d molecules are rapidly transported via Golgi to the plasma 
membrane through the secretory route. Further, CD1d is recycled from the 
membrane. Directed by the cytoplasmic tail of CD1d, it internalizes from the 
plasma membrane via clathrin coated pits and moves through early and late 
endosomes to the lysosome [33]. The transport of CD1d from the plasma 
membrane to endosomes requires the adaptor protein (AP) complex AP-2, 
after which an AP-3 dependent transport of CD1d from endosomes to the 
lysosome takes place (figure 1). Studies have shown that CD1d binds 
endogenous lipids, including glycosylphosphatidylinositols (GPIs) in ER [34-
36] that may be exchanged for other lipids when CD1d is recycled through 
endosomal and lysosomal compartments. As for today, GPIs have not been 
shown to be antigenic for NKT cells, which suggests that GPIs might 
function as chaperons, facilitating the assembly of CD1d molecule in ER.  
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Figure 1. Mouse CD1d trafficking.  CD1d heavy chain assembles with β2-
microglobulin (β2m) in endoplasmic reticulum (ER) where it binds ER derived 
self-lipids and further transport via the Golgi complex to the plasma membrane 
takes place. From the plasma membrane, CD1d is internalized through clathrin 
coated pits and is directed to endosomes by adaptor protein complex (AP)-2 and 
further to the lysosome by AP-3. In endosomes and lysosome, ER derived self-
lipids on CD1d can be replaced with other self or foreign lipids, followed by 
transport back to the plasma membrane.     
NKT cells 
The history of NKT cells 
In 1986, Taniguchi and colleagues described a Vα14–Jα18 TCRα chain 
cloned from a suppressor T cell hybridoma [37]. A few years later, a 
population of TCRαβ cells expressing the NK marker NK1.1 was discovered 
in C57BL/6 mice and named NKT cells [38, 39]. Further investigations 
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demonstrated that these Vα14–Jα18 invariant TCRα chain expressing cells 
were CD1d restricted [40], autoreactive, and differed from conventional T 
cells in that they expressed intermediate levels of TCR, had a bias toward 
Vβ8 expression and notably, produced high levels of immunoregulatory 
cyokines such as IFN-γ and IL-4 (reviewed in [39, 40]). In 1995, Cardell and 
colleagues found a population of CD1d restricted TCRαβ cells [41]. Instead 
of the invariant Vα14–Jα18 TCRα chain, these cells expressed a diverse set 
of TCR α- and β-chains [43]. A couple of years later, Kawano et al 
discovered that the Vα14–Jα18 expressing NKT cells recognized the GSL α-
galactosylceramide (α-GalCer) derived from a marine sponge [44]. 
Subsequently, α-GalCer loaded on CD1d tetramers could be used as a tool to 
study Vα14–Jα18-expressing NKT cells [45, 46] which significantly helped 
to move the NKT cell research field forward. Following the discovery of α-
GalCer, investigations on Vα14–Jα18 TCR expressing NKT cells increased 
extensively, while the lack of specific reagents has limited the studies of the 
non-Vα14–Jα18 expressing NKT cells. However, in 2004 there was a 
breakthrough in the study of these NKT cells. The GSL sulfatide was 
demonstrated as a CD1d-restricted ligand for a subset of non- Vα14–Jα18 
NKT cells, which allowed further studies of this novel CD1d-restricted NKT 
cell population [30].  
Definition of NKT cells 
The consensus in the field is that NKT cells are defined as CD1d restricted 
TCRαβ cells, and this is the definition that will be used throughout this 
thesis. Two main subsets of NKT cells have been described. Type I NKT 
cells (or invariant NKT) bearing the Vα14-Jα18 (mouse) TCR α-chain 
paired with Vβ8.2, Vβ7 or Vβ2, or the corresponding segments Vα24- Jα18 
in humans, paired with Vβ11. Type II NKT cells (or diverse NKT), in 
contrast, carry diverse TCRs [42, 43]. In addition to TCRs or BCRs, NKT 
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cells also express receptors that do not require gene recombination, and are 
generally not expressed by conventional lymphocytes. These receptors sense 
cellular stress, such as during infections and are divided into activating 
receptors, which include NKG2D and NK1.1, and inhibitory NK receptors 
such as NKG2A [44].  
NKT cell subsets 
Dividing the NKT cell subsets 
The subdivision of NKT cells according to their expression of TCRs is one 
way of distinguishing different NKT cells. In addition, NKT cells can be 
divided by their expression of CD4 and CD8 [45]. In mice, type I NKT cells 
are either CD4+ or CD4-CD8- (double negative, DN). However, in humans, 
CD4-CD8+ NKT cells also exist. In humans, a difference in function of CD4+ 
and DN type I NKT cells has been shown [42, 46, 47]. CD4+ NKT cells were 
shown to produce cytokines of both Th1 and Th2 type, including both IFN-γ 
and IL-4, whereas the major cytokine production by DN NKT cells was of 
Th1 type, suggesting that the expression profile of CD4 and CD8 divides 
NKT cell cells into functionally different subsets. Further, DN type I NKT 
cells seem to express more NK receptors, such as NK.1.1, 2B4, NKG2A and 
NKG2D [46-48], suggesting that they are more similar to NK cells in 
comparison to CD4+ NKT cells. Further, it was shown that DN type I NKT 
cells more efficiently induced protection against methylcholanthrene-induced 
sarcomas in mice [49] and when comparing cells from spleen, liver and 
thymus it was shown that liver derived DN type I NKT cells were required 
for rejection of sarcomas. This suggests that not only the expression of CD4 
or CD8 contributes to distinguish functional differences of NKT cells, in 
addition different tissue locations seems to provide NKT cells of diverse 
functions. Whether the expression profile of CD4 and CD8 goes together 
with functional differences in type II NKT is not well explored. However, 
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Kadri et al demonstrated that TCR transgenic DN type II NKT cells express 
higher levels of NK markers such as CD49b, Ly49G2, and CD122 in 
comparison to the CD4+ population, and only CD4+ cells could prevent type 1 
diabetes induction [43], suggesting that also type II NKT cells may be 
divided into functionally different subsets according to CD4 expression.  
Type I NKT cells 
Through the use of α-GalCer loaded CD1d tetramers, type I NKT cells have 
been extensively studied. In mouse thymus, type I NKT cells represent 
∼0,5% of all thymocytes [48] and in the liver where they are most abundant, 
they represent as much as ∼30% of the T cell population. In spleen, they 
represent ∼ 2,5% of all T cells and in peripheral lymph nodes and blood, they 
represent a population of ∼0,5% of T cells. In liver, type I NKT cells seem to 
patrol the sinusoids and during steady state condition, they stay in the liver by 
their expression of CXCR6, the receptor for CXCL16, expressed by 
endothelial cells lining the sinusoids [27]. In addition, high expression of 
CD1d on liver resident Kupffer cells seems to be important for retaining the 
NKT cells in the liver [27]. Further, the expression of lymphocyte function 
associated antigen 1(LFA-1) and the interaction with intracellular adhesion 
molecule 1 (ICAM-1) expressed on NKT cells as well as production of 
interleukin (IL) -15 by hepatic stellate cells (Ito) appear crucial for the 
maintenance of NKT cells in liver [50]. Recently, a subset of type I NKT 
cells that lack NK1.1 and produces high amounts of IL-17 and low amounts 
of IFN-γ and IL-4 has been identified [57]. It was demonstrated that these IL-
17 producing NKT cells were highly abundant in lungs. During airway 
neutrophilia induced by endotoxin exposure, they significantly increased the 
inflammation. Notably, in humans, the frequencies of type I NKT cells 
appear to be lower, approximately ten times less than the population observed 
in mice [51].  
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Type II NKT cells  
In contrast to the semi-invariant TCR expressed by type I NKT cells, type II 
NKT cells express diverse TCRs and are non responsive towards α-GalCer. 
Analysis of autoreactive, CD1d restricted, non-Vα14 T hybridoma cells 
derived from short term TCRβ activated CD4+, NK1.1 positive or negative 
splenocytes from MHC class II–deficient mice demonstrated a bias towards 
Vα3.2-Jα9, together with Vβ8-chains [52]. This suggests that the type II NKT 
cell population might include subpopulations that are invariant and may be 
activated by the same lipid antigens. Interestingly, a population of non-Vα14, 
α-GalCer reactive cells has been identified [53]. This NKT cell population 
expresses Vα10-Jα50 pared with Vβ8 and is named “Vα10 NKT cells”. 
Similar to type I NKT cells, Vα10 NKT cells recognize α-GalCer and 
isoglobotrihexosylceramide (iGb3), however showed a preference for α-
glucosylceramide (α-GlcCer). In addition, Vα10 NKT cells are strongly 
activated by the microbial lipid ligand α-glucuronosyl diacylglycerol (α-
GlcA-DAG) derived from Mycobacterium smegmatis. Vα10 NKT cell 
produced 10- to 100-fold more IL-4, IL-13 and IL-17A than did type I NKT 
cells in response to α-GlcA–DAG, suggesting that they are functionally 
distinct. Further, sulfatide reactive cells belong to the type II NKT cell subset. 
When using sulfatide loaded CD1d tetramers, Kumar and colleagues could 
demonstrate a population of ∼ 5% of T cells in liver and ∼ 0,2% of T cells in 
spleen that stained positive. This represents approximately 20% the size of 
the type I NKT cell population in these organs. Further, human type II NKT 
cells have been shown to recognize lyso-phosphatidylcholine (LPC) isolated 
from plasma derived from multiple myeloma patients. These cells produced 
high levels of IL-13 and were found at increased frequencies in patients with 
multiple myeloma compared to healthy individuals [54].  
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These data strengthen the concept that there are, indeed, subpopulations of 
type II NKT cells expressing invariant TCR and/or having shared lipid 
antigen specificity. As a consequence of their diverse TCR, no universal lipid 
antigen can be expected to identify the entire population of type II NKT cells. 
As a result of the inability to identify the entire type II NKT cell population, 
the only certain way to investigate the type II NKT cells is through their 
CD1d restriction and the expression of non-Vα14 TCRα chains. 
Development of T lymphocytes in the 
thymus 
Thymus provides the microenvironment essential for the development of T 
cells from hematopoietic stem cells. From early thymic progenitors, DN cells 
develop through four stages (DN1-DN4) distinguished by differential 
expression of CD25, CD44, and CD117. At the DN2 stage, the 
rearrangement at the TCRγ, TCRδ, and TCRβ gene loci is initiated which is 
completed at the DN3 stage [55, 56], where αβ versus γδ T cell fate is 
specified [57]. The γδ rearrangements at the DN2 stage can give rise to γδ T 
cells already at this stage. Further, the maturation of αβ-thymocytes involves 
expression of the pre-TCR that induces the expression of CD4 and CD8, and 
transition to the DP stage and initiation of TCRα recombination. The TCRα 
is randomly rearranged and for type I NKT cells, the formation of Vα14-
Jα18 allows the recognition of selecting self-lipids presented on CD1d after 
pairing with an appropriate TCRβ chain. Thus, at the DP stage, positive 
selection of αβ-thymocytes takes place and NKT cell development diverges 
from that of conventional T cells.  
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NKT cell development 
The development of NKT cells is distinct from that of conventional T cells 
even though they originate from the same DP precursor. The study of NKT 
cell development has been possible by the use of α-GalCer tetramers specific 
for the type I NKT cells. Due to the lack of unique reagents for type II NKT 
cells, most information available describes the development of type I NKT 
cells. At the DP stage, DP cells to become NKT cells are positively selected 
by other DP thymocytes expressing self-lipid CD1d complexes (figure 2). 
This is in contrast to the selection of conventional T cells, which have been 
selected by cortical thymic epithelial cells, bearing MHC molecules. The 
different stages of thymic NKT cell development, and important factors for 
each stage, is depicted in figure 2. The selection of NKT cells by CD1d 
expressing self-lipids induces an activated memory phonotype already at 
“stage 0” in development, which is distinct from the naïve phenotype of 
mature conventional single positive (SP) thymocytes. NKT cells are only 
selected when CD1d is expressed on DP thymocytes [31, 58-62], indicating 
that DP thymocytes possess crucial signals that are significant for positive 
selection of NKT cells, and/or that DP thymocytes have a unique capacity of 
presenting lipids required for selection of NKT cells. CD1d-/- mice, or mice 
with defects in CD1d processing and presentation, lack mature NKT cells 
[63]. The positive selection event by CD1d-lipid complex with TCR requires 
ligation of both TCR and a costimulatory molecule, signaling lymphocytic 
activation molecule (SLAM) that signals via SLAM-associated protein (SAP) 
and the downstream Src kinase (FynT) [64-66]. In comparison to 
conventional T cells that depend on the Ras-MAP kinase pathway (RAS-
Mek1), this pathway seems dispensable for NKT cells. In contrast, NKT cells 
are deficient in mice lacking FynT, demonstrating the importance of SLAM-
SAP-FynT signaling pathway in the developmental program of NKT cells 
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[67, 68]. Also, at this point, induction of promyelocytic leukemia zinc finger 
(PLZF) and runt related transcription factor 1 (Runx1), and subsequently 
myelocytomatosis oncogene (c-Myc) transcription factor and early growth 
response (Egr) transcription factor 2 appears to be important. PLZF is 
expressed during the complete development of typ I NKT cells, starting after 
the positive selection of DP thymocytes to the terminally differentiated stage 
of NKT cell development in peripheral tissues [69]. With exception of two 
other innate-like lympocyte, the MR1-restricted, mucosal-associated 
invariant T (MAIT) cells and γδ T cells [70], PLZF is only detected at high 
levels in NKT cells. Following successful CD1d-TCR ligation, NKT cells 
enter “stage 0” indicated by expression of CD24, CD4 and CD69 (CD24high, 
CD4+, CD8low and CD69high). Further maturation occurs through 
downregulation of CD24 and CD8 to reach the mature CD4+ NKT cell stage 
with low expression of CD44 in “stage 1”. These “stage 1” NKT cells remain 
in thymus where they continue their developmental program into “stage 2” by 
upregulating CD44 and IL-15β receptor (CD122) that mediate the induction 
of low basal transcription of Th2 followed by Th1 cytokines. Upon leaving 
the thymus, NKT cells starts to express NK lineage receptors such as NK1.1 
and enter “stage 3”. The transcription factor T-bet is essential for the 
transition from “stage 2” to “stage 3”. Some NKT cells in “stage 3” reside in 
the thymus (figure 2), however, with as yet unknown functions. Upon leaving 
the thymus, NKT cells preferentially migrate to the liver, however they are 
also present in spleen, bone marrow, lung and gut. The frequencies in lymph 
nodes (LN) are relatively low due to the lack of expression of homing 
receptors such as CD62L and CCR7 on NKT cells (reviewed in [38, 63, 71]). 
Notably, an IL-17 producing subset of type I NKT cells, mentioned above, is 
abundant in the lung, inguinal LN, and mesenteric LN, but hardly detectable 
in the liver and bone marrow (BM) of both C57BL/6 and BALB/c mice. This 
distinct NKT cell population expresses CCR7, in contrast to other type I 
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NKT cells. This suggests that there might be functionally distinct populations 
of NKT cells that locate specifically to these locations [72] [73].  
 
Figure 2. Type I NKT cell development. NKT cells diverge from conventional T 
cell development when the TCR interact with CD1d expressing self-lipids. The 
positive selection event by CD1d-lipid complex with TCR requires ligation of 
both TCR and a costimulatory molecule, signaling lymphocytic activation 
molecule (SLAM) that signals via SLAM-associated protein (SAP) and the 
downstream Src kinase (FynT). Further development of NKT cells occurs in a 
stepwise manner, “stage 0” to “stage 3”, where expression of different 
transcription factors as well as cell surface proteins differs. At “stage 2”, NKT 
cells leave the thymus and complete the development peripherally. Some NKT 
cells stay in thymus as “stage 3”. 
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NKT cell activation 
NKT cells have various functions in the immune system. They have the 
capacity of rapidly and robustly producing a range of different cytokines as 
well as the capacity of killing other cells [74]. Type I NKT cells express high 
levels of granzyme B, perforin and FasL consistent with their cytotoxic 
capacity. The dual production of IFN-γ and IL-4 has been a hallmark in terms 
of NKT cell activation. Indeed, the secretion of IFN-γ and IL-4 by type I 
NKT cells has been shown as early as 2 hours after in vivo exposure to α-
GalCer [75]. High levels of IFN-γ and IL-4 mRNAs in resting NKT cells is 
provided as an explanation for this rapid response and subsequent cytokine 
release [4, 76]. Consequently they have an “activated-yet memory” 
phenotype. The fact that NKT cells can produce both inflammatory and anti-
inflammatory cytokines (figure 3A) is key to their importance in different 
diseases, such as autoimmunity, infection, cancer and allergy (reviewed in 
[38]). The role of NKT cells in some of these diseases will be brought up 
later in this thesis.  
Interestingly, CD1d is a non-polymorphic molecule, in contrast to MHC 
molecules, which are highly polymorphic. This suggests that CD1d carries 
out conserved antigen presenting functions [77]. The activation of NKT cells 
can occur in different ways, and involve distinct activation systems. Since 
NKT express receptors of both NK cells and T cells, they are capable of 
being activated by TCR-CD1d-lipid interactions (figure 3B, D-E), through 
non-rearranged innate receptors such as NK receptors (figure 3F) [78], as 
well as by cytokines (figure 3C). During the course of infection, NKT cells 
can be activated by a direct presentation of bacterially derived lipids [79-83] 
(figure 3D). Notably, some bacterial lipid antigens stimulating NKT cells via 
CD1d are derived from lipopolysaccharide (LPS) deficient gram-negative 
bacteria, and it has been suggested that bacterially derived lipids may 
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function as substitutes to the lack of PAMPs such as LPS to activate NKT 
cells (reviewed in [38]). Further, bacterial infections can modulate GSL 
synthesis in APC by either increasing biosynthesis or inhibiting degradation 
enzymes, which leads to accumulation of GSLs known to stimulate NKT 
cells [84, 85]. The recognition of PAMPs by toll like receptors (TLRs) on 
APCs has been shown to induce presentation of stimulatory self-lipids to 
NKT cells (figure 3B) [84, 85], demonstrating that lipid synthesis and 
presentation of self-lipids are altered during TLR engagement. In addition, 
during infections, NKT cells can be activated by TCR independent 
mechanisms including cytokines released by APCs. These cytokines include 
type I IFN, IL-12 and IL-18 [86, 87]. Further, theoretically, NKT cells could 
also be activated by lipid ligands derived from damaged tissues (figure 3E). 
For instance, sulfatide present in β-cells of pancreatic islets or CNS [88] 
might be taken up by APCs and be presented to type II NKT cells.   
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Figure 3. Different modes of NKT cell activation. (A) NKT cells have different 
functions in the immune system; they posses killing activity, and they produce an 
array of different cytokines and chemokines upon activation through (B) the 
induction of stimulatory endogenous self-lipids in response to pathogenic 
microbes, or (C) they can be activated by the release of cytokines from activated 
APCs that have encountered bacteria, or (D) a direct presentation of bacterially 
derived lipid antigens. (E) Hypothetically NKT cells can also be activated by 
tissue derived self-lipids from destructed tissues. (F-G) Further, NK cell receptors 
can mediate activation or inhibition of activation of NKT cells. Modified from 
[74]. 
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NKT cell ligands 
The diversity of recognized lipid antigens  
The interaction between lipid-CD1d complex and the NKT cell TCR 
represents a central event in NKT cell activation. As for today, a great 
diversity of lipids presented on CD1d and stimulating NKT cells has been 
demonstrated. One major difference between bacterial lipids and mammalian 
lipids is the linkage of the sugar to the lipid backbone. Bacterial lipids have 
α-linkage, whereas mammalian lipids are β-linked. Interestingly, both types 
of lipids can bind to CD1d and activate NKT cells. Thus, despite the 
conserved structure of CD1d, it can bind to an array of different lipid-based 
antigens [38, 39, 74, 89-98].  
Bacterial ligands 
In 1997, Kawano et al discovered that the marine sponge derived GSL α-
GalCer efficiently stimulates type I NKT cells [99]. It is thought that α-
GalCer is a bacterially derived lipid produced by a putative bacterium that is 
symbiotic with the sponge. Since the discovery of α-GalCer, several 
microbial ligands have been demonstrated to activate type I NKT cells [53, 
79-81, 83, 100-104]. Using soluble murine CD1d bound to plastic, Fischer et 
al. identified phosphatidylinositol mannoside (PIM) with four mannose 
residues and two saturated palmitate (C16) acyl chains (PIM4) derived from 
Mycobacterium tuberculosis as an activating mycobacterial lipid ligand for 
type I NKT cells [103]. PIM4 induced CD1d dependent IFN-γ production by 
splenic type I NKT cells, isolated from Vα14-Jα18 transgenic mice. In 
contrast to stimulation with α-GalCer, no IL-4 was produced in the PIM4 
stimulated cultures. Staining with PIM4 loaded CD1d tetramers demonstrated 
that 0.26% of liver NKT cells (CD3+NK1.1+) and 0.6% of splenic NKT cells 
(CD3+NK1.1+) stained positive. The low frequencies of PIM4 positive, type I 
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NKT cells indicate that the β-chain might influence the interaction with PIM4 
to a greater extent than with α-GalCer, resulting in a subpopulation of type I 
NKT cells recognizing PIM4.  
Ever since α-GalCer was demonstrated as a ligand for type I NKT cells, 
GSLs have been a focus in the search for lipid antigens activating NKT cells. 
The cell wall of Sphingomonas paucimobilis contains α-
glucuronosylceramide (α-GlcUCer) that was demonstrated as a ligand for 
type I NKT cells [82, 83]. The use of α-GlcUCer loaded CD1d dimers 
demonstrated that 0.5% of liver α-GalCer positive NKT cells stained 
positive, again pointing to a decisive role for the TCR β-chain of the type I 
NKT TCR in the recognition of certain bacterial lipids. Further, the highly 
pathogenic gram-positive bacterium Borrelia burgdorferi that causes Lyme 
disease contains stimulatory lipid ligands of the family α-
galactosyldiacylglycerols (αGalDAGs) for type I NKT cells [81]. αGalDAGs 
loaded tetramers stained a population in liver that was 23% of the α-GalGer 
positive cells. Another highly pathogenic gram-positive bacterium, 
Streptococcus pneumoniae as well as the gram-positive pathogen, group B 
Streptococcus have been demonstrated to contain activating lipid ligands 
such as α-glucosyldiacylglycerols (αGlcDAGs) for type I NKT cells [102].   
Endogenous ligands 
Autoreactivity  
The TCR selection of DP thymocytes by CD1d expressed on DP cells, 
initiates the developmental program that provides NKT cells with their 
unique charachteristics such as autoreactivity. Hence NKT cells have been 
termed “autoreactive by design” [105]. This natural autoreactivity is easily 
demonstrated in in vitro assays using NKT cell hybridomas. Several NKT 
cell hybridomas derived from both type I and type II NKT cells are 
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The diversity of recognized lipid antigens  
The interaction between lipid-CD1d complex and the NKT cell TCR 
represents a central event in NKT cell activation. As for today, a great 
diversity of lipids presented on CD1d and stimulating NKT cells has been 
demonstrated. One major difference between bacterial lipids and mammalian 
lipids is the linkage of the sugar to the lipid backbone. Bacterial lipids have 
α-linkage, whereas mammalian lipids are β-linked. Interestingly, both types 
of lipids can bind to CD1d and activate NKT cells. Thus, despite the 
conserved structure of CD1d, it can bind to an array of different lipid-based 
antigens [38, 39, 74, 89-98].  
Bacterial ligands 
In 1997, Kawano et al discovered that the marine sponge derived GSL α-
GalCer efficiently stimulates type I NKT cells [99]. It is thought that α-
GalCer is a bacterially derived lipid produced by a putative bacterium that is 
symbiotic with the sponge. Since the discovery of α-GalCer, several 
microbial ligands have been demonstrated to activate type I NKT cells [53, 
79-81, 83, 100-104]. Using soluble murine CD1d bound to plastic, Fischer et 
al. identified phosphatidylinositol mannoside (PIM) with four mannose 
residues and two saturated palmitate (C16) acyl chains (PIM4) derived from 
Mycobacterium tuberculosis as an activating mycobacterial lipid ligand for 
type I NKT cells [103]. PIM4 induced CD1d dependent IFN-γ production by 
splenic type I NKT cells, isolated from Vα14-Jα18 transgenic mice. In 
contrast to stimulation with α-GalCer, no IL-4 was produced in the PIM4 
stimulated cultures. Staining with PIM4 loaded CD1d tetramers demonstrated 
that 0.26% of liver NKT cells (CD3+NK1.1+) and 0.6% of splenic NKT cells 
(CD3+NK1.1+) stained positive. The low frequencies of PIM4 positive, type I 
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NKT cells indicate that the β-chain might influence the interaction with PIM4 
to a greater extent than with α-GalCer, resulting in a subpopulation of type I 
NKT cells recognizing PIM4.  
Ever since α-GalCer was demonstrated as a ligand for type I NKT cells, 
GSLs have been a focus in the search for lipid antigens activating NKT cells. 
The cell wall of Sphingomonas paucimobilis contains α-
glucuronosylceramide (α-GlcUCer) that was demonstrated as a ligand for 
type I NKT cells [82, 83]. The use of α-GlcUCer loaded CD1d dimers 
demonstrated that 0.5% of liver α-GalCer positive NKT cells stained 
positive, again pointing to a decisive role for the TCR β-chain of the type I 
NKT TCR in the recognition of certain bacterial lipids. Further, the highly 
pathogenic gram-positive bacterium Borrelia burgdorferi that causes Lyme 
disease contains stimulatory lipid ligands of the family α-
galactosyldiacylglycerols (αGalDAGs) for type I NKT cells [81]. αGalDAGs 
loaded tetramers stained a population in liver that was 23% of the α-GalGer 
positive cells. Another highly pathogenic gram-positive bacterium, 
Streptococcus pneumoniae as well as the gram-positive pathogen, group B 
Streptococcus have been demonstrated to contain activating lipid ligands 
such as α-glucosyldiacylglycerols (αGlcDAGs) for type I NKT cells [102].   
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termed “autoreactive by design” [105]. This natural autoreactivity is easily 
demonstrated in in vitro assays using NKT cell hybridomas. Several NKT 
cell hybridomas derived from both type I and type II NKT cells are 
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autoreactive towards different CD1d expressing APCs without the addition of 
exogenous lipid antigens [40, 41, 106, 107]. In addition, several studies show 
that the autoreactivity of NKT cells can be increased by altered presentation 
of endogenous ligands during infections or APC activation. Based on current 
knowledge, figure 4 depicts different circumstances of CD1d-dependent NKT 
cell autoreactivity, where we call the latter situation "Induced peripheral 
autoreactivity". We suggest that the CD1d-dependent autoreactivity that is 
demonstrated by NKT hybridomas to APC in vitro may represent a low 
degree of autoreactivity of NKT TCR in vivo to resting APC, and have 
termed this "Steady state peripheral autoreactivity" (as in figure 4), or natural 
autoreactivity. Whether the lipids required for TCR selection of NKT cells in 
thymus (the first mode of autoreactivity in figure 4) are playing a role in the 
peripheral steady state or induced autoreactivity of NKT cells is not known, 
nor if peripheral steady state and induced autoreactivity depend on the same 
or overlapping ligands. Below, we will use these terms to describe different 
modes of NKT cell autoreactivity. 
 
Figure 4. Self-lipids are involved in the positive selection of NKT cells in the 
thymus, as well as in "steady state" and "induced" autoreactivity in the 
periphery. As for today, whether the lipids presented on CD1d in these three 
situations are the same, overlapping or completely different is not known.  
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Type I NKT cell ligands 
Due to potent regulatory properties of NKT cells, extensive studies have 
focused on identifying how they can be activated and especially the ligands 
underlying their CD1d-dependent autoreactivity. In 2000, Gumperz at al. 
demonstrated that both type I and type II NKT cell hybridomas were 
activated by phospholipids derived from a tumor cell line [108] when 
presented on plate-bound CD1d. Phospholipids derived from the tumor cells 
included phospholipids such as phosphatidylinositol, 
phosphatidylethanolamine and phosphatidylglycerol. Further, Stanic et al 
demonstrated that β-GlcCer deficient APCs (APCs deficient in 
glucosylceramide synthase (GCS), see figure 5) fail to stimulate type I NKT 
cell autoreactivity [109]. Further, they found that β-GlcCer itself did not 
stimulate type I NKT cells indicating that lipids downstream of β-GlcCer, 
dependent on β-GlcCer synthesis, could be responsible for the autoreactivity 
of type I NKT cells. The following year, Zhou et al identified iGb3 as an 
activating ligand for type I NKT cells [110]. Mice deficient in the lysosomal 
glycosphingolipid degrading enzyme β-hexosaminidase b subunit (Hexb–/–, 
see figure 5) were shown to exhibit a significant decrease in type I NKT cells. 
Cells staining positive with α-GalCer tetramers were reduced by 95%. This 
suggested that iGb3 is involved in the thymic positive selection of NKT cells. 
A report from another group seemed to confirm the role of iGb3 as a ligand 
for type I NKT cells, demonstrating that deficiency in αGalA (as in αGalA-/- 
mice and human Fabry disease. See figure 5), resulting in accumulation of 
iGb3 as well as Gb3, caused overstimulation and deletion of type I NKT cells 
[85]. In contrast, a subsequent study demonstrated that mice deficient in iGb3 
synthase (iGb3S) have normal development of type I NKT cells with no 
functional abnormalities, suggesting that iGb3 is unlikely to be involved in 
thymic development of type I NKT cells [111]. It also remains controversial 
whether iGb3 is involved in thymic selection of type I NKT cells in humans 
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autoreactivity". We suggest that the CD1d-dependent autoreactivity that is 
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degree of autoreactivity of NKT TCR in vivo to resting APC, and have 
termed this "Steady state peripheral autoreactivity" (as in figure 4), or natural 
autoreactivity. Whether the lipids required for TCR selection of NKT cells in 
thymus (the first mode of autoreactivity in figure 4) are playing a role in the 
peripheral steady state or induced autoreactivity of NKT cells is not known, 
nor if peripheral steady state and induced autoreactivity depend on the same 
or overlapping ligands. Below, we will use these terms to describe different 
modes of NKT cell autoreactivity. 
 
Figure 4. Self-lipids are involved in the positive selection of NKT cells in the 
thymus, as well as in "steady state" and "induced" autoreactivity in the 
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thymic development of type I NKT cells [111]. It also remains controversial 
whether iGb3 is involved in thymic selection of type I NKT cells in humans 
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[112]. Moreover, in a recent study using αGalA-/-/iGb3S-/- (αGalA and 
iGb3S, see figure 5) double knockout mice, unable to degrade Gb3 and iGb3 
and deficient in iGb3, the number of type I NKT cells decreased to the same 
extent as in αGalA-/- deficient mice, unable to degrade Gb3 and iGb3. The 
conclusion from this last study was therefore that the accumulation of Gb3 
and not iGb3 was was sufficient to decrease the number of type I NKT in the 
αGalA-/-/iGb3S-/- double deficient mice. Consequently, they proposed that it 
was accumulation of Gb3 rather than iGb3 that caused type I NKT cell 
deficiency also in the  αGalA-/- single deficient mice [113].  
The demonstration that several self-GSLs stimulated type I NKT cells and 
influenced their development, suggested that GSLs might be required for the 
autoreactivity of type I NKT cells. However, in 2011, Pei et al demonstrated 
that the autoreactivity of type I NKT cells did not require GSLs [114], by 
using APCs deficient in sphingosine long-chain base subunit 1 (LCB1, see 
figure 5) and subsequently have a dramatic deficiency in GSLs and 
sphingomyelin. The independence of GSLs in the autoreactivity of type I 
NKT cells was demonstrated with both NKT hybridoma cells and primary 
TCR transgenic type I NKT cells. Interestingly, this suggested that GSLs are 
not required for natural autoreactivity of type I NKT cells, yet there are GSLs 
that can activate type I NKT cells. The following year, it was demonstrated 
that β-GlcCer accumulates in APC after LPS stimulation and contributes to 
type I NKT cell activation during Escherichia coli, Pseudomonas 
aeruginosa, Staphylococcus aureus, Streptococcus pneumoniae or Listeria 
monocytogenes bacterial infection [115]. This indicates that the GSL β-
GlcCer functions as a self-lipid ligand, responsible for induced autoreactivity 
of type I NKT cells during infections. Even though β-GlcCer plays a role as a 
self-lipid ligand in peripheral autoreactivity of type I NKT cells, its function 
in thymic development is not clear. In 2012, Facciotti et al demonstrated that 
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the ether-bonded plasmalogen C16-lyso-phosphatidylethanolamine (pLPE), 
derived from mouse thymocytes activates type I NKT cells [116]. Mice 
lacking glyceronephosphate O-acyltransferase, and thereby deficient in ether-
lipid synthesis and plasmalogens, have reduced numbers of type I NKT cells 
and impaired ability to activate and promote full maturation of type I NKT 
thymocytes. This suggests that pLPE is involved in the positive selection of 
type I NKT cells. Further, tumor associated disialoganglioside (GD3) has 
been demonstrated to activate type I NKT cells [117]. In mice immunized 
with a human melanoma cell line expressing GD3, 0.29 % of CD3+ T cells in 
spleen stained positive for CD1d-tetramer loaded with GD3, while these cells 
were not detected in non-immunized mice. In addition, lyso-
phosphatidylcholine (LPC) and lyso-sphingomylein (LSM) activate a fraction 
of human type I NKT cells [118].  
Type II NKT cell ligands  
The first lipid ligand described to activate type II NKT cells was sulfatide 
[30].  Jahng and colleagues demonstrated that sulfatide is a ligand for type II 
NKT cells and that sulfatide administration protected mice from developing 
experimental autoimmune encephalomyelitis (EAE), a mouse model for 
multiple sclerosis (MS). Further, sulfatide has been shown to be recognized 
by CD1a-, CD1b-, and CD1c- restricted human T cells, indicating that the 
same self-lipid antigen can, in some cases, be presented by different CD1 
isoforms [119]. The activation of mouse type II NKT cells by CD1d 
presentation of sulfatide will be discussed in detail later in this thesis.  
LPC derived from plasma of myeloma patients has been demonstrated to 
activate human type II NKT cells [54], and LPC specific T cells increase in 
myeloma patients, compared to healthy individuals. Further, a recent 
publication demonstrated that during hepatitis B infection, lyso-
phospholipids are produced in infected hepatocytes by the action of secretory 
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LPC derived from plasma of myeloma patients has been demonstrated to 
activate human type II NKT cells [54], and LPC specific T cells increase in 
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phospholipases and subsequently presented on CD1d resulting in the 
activation of type II NKT cells [120]. Among lipids induced by the secretory 
phospholipase A2 (sPLA2), the activating lipid ligands lyso-
phospatidylethanolamine (LPE) with different sphingosine bases, as well as 
C18:1 lyso-LPC were identified.  Further, it was demonstrated that the 
CD1d-dependent activation of type II NKT cells by these lyso-phospholipids 
induced downstream activation of type I NKT cells by an indirect, TCR 
independent mechanism. Further, in 2005, Agea at el. demonstrated that 
phosphatidylcholine (PC) and phosphatidylethanolamine (PE) derived from 
cypress pollen grains were able to stimulate the proliferation of CD1d 
restricted non-Vα24 NKT cells from cypress sensitive individuals [121]. The 
major type of both PC and PE had 18:2/18:2 fatty acids.  
Non-lipid ligands 
Early reports have shown a peptide binding capacity of CD1d demonstrating 
that antigens presented on CD1d may not be limited to lipidic molecules [15, 
122-124]. Further, human type II NKT cells have been described to recognize 
a small non-lipidic molecule derived from a mixture of acetylated synthetic 
lipopeptides [19]. This non-lipidic molecule was identified as 9-fluorenyl 
methyloxycar-bonyl-N�-2,2,4,6,7-pentamethyldihydrobenzofuran-5-
sulfonyl-L-arginine (PPBF) and was shown to induce activation of non-Vα24 
NKT cells. Further, CD1d has been demonstrated to bind non-polar 
hydrophobic fluorescent probes, named anilinonaphthalene sulfonic acid 
(ANS) [125]. These probes become fluorescent when bound to hydrophobic 
regions of proteins and thereby it was possible to measure their binding to 
CD1d. In addition, a recent report illustrate that the type II collagen peptide 
707-721 (CII707-721) was presented on CD1d, and that CII707-721-specific 
CD1d-restricted NKT cells produce IL-4, IFN-γ, IL-17A, TNF-α, and TGF-β 
upon peptide stimulation [15, 122-124]. 
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Glycosphingolipids 
Biosynthesis of GSL 
The term glycosphingolipid applies to compounds that contain a ceramide 
base connected to a monosaccharide or more complex saccharide structures 
[126]. GSLs can be subdivided into neutral or acidic groups where neutral 
GSLs involve the globo-, lacto-, neoacto- and ganglio series, while the acidic 
GSLs are the sialic acid carrying gangliosides and sulfated GSLs such as 
sulfatide (figure 5). GSLs are believed to play important roles in a variety of 
cellular processes, such as cell recognition, growth, development and 
differentiation. The biosynthesis and degradation of GSLs involves numerous 
enzymes that act at various subcellular locations.  
 
Figure 5. GSL metabolism. GSLs are subdivided in neutral or acidic groups, 
where neutral GSL are the globo-, lacto- and neolacto, and ganglio-series, and the 
acidic GSL are the gangliosides and sulfated GSLs. Enzymes involved in 
synthesis and degradation are shown in red. Modified from [113] 
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The biosynthesis of GSLs occurs in a stepwise manner, where the first step is 
the addition of a single carbohydrate moiety to an acceptor lipid substrate, 
ceramide [127]. Initially, the biosynthesis of GSLs occurs in the membranes 
of ER, where ceramide is synthesized (figure 6). Thereafter, ceramide is 
translocated from the cytoplasmic face of ER to the luminal side of Golgi 
apparatus by the transport protein CERT. On the luminal side, sphingomyelin 
synthase 1 converts ceramide into sphingomyelin (SM) by transfer of a 
phosphorylcholine headgroup from phosphoglycerolipids. In addition, 
through the action of glucosylceramide synthase (GCS, see figure 5), 
synthesis of GlcCer occurs at the cytoplasmic face of ER as well as in early 
Golgi (cis) and subsequently flips into the Golgi lumen, where synthesis of 
more complex GSLs take place by a series of glucosyltransferases (the GSL 
series are shown in figure 5) (reviewed in [127]). These complex GSLs 
consist of α and β-linked glucose, galactose, N-acetylglucosamine, and/or N-
acetylgalactosamine. Many of these complex GSLs have one or more sialic 
acid residues in their glycan structure and are named gangliosides [128]. In 
comparison to GlcCer, GalCer synthesis occurs on the luminal face of the ER 
and then traffics through the Golgi, where it may be sulfated to from sulfatide 
or more complex sulfated GSLs. During synthesis and passage through the 
ER/Golgi compartments, GSL may be available for loading on newly 
synthesized CD1d (see figure 1 and 6), however, isolation of lipids loaded on 
CD1d in these compartments have revealed a dominance of 
glucosylphosphatidylinositol [34].  
From Golgi, synthesized GSLs are transported via vesicles to the plasma 
membrane where the GSLs become part of the membrane, facing the 
extracellular milieu. Through invaginated vesicles, GSLs and other 
components of the plasma membrane are internalized into endosomes. This 
results in the glycan structure of GSLs facing the endosomal lumen. Fusion 
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of endosomes with lysosomes makes the GSLs available for cleavage into 
smaller structures, by lysosomal hydrolases with the help from activator 
proteins such as saposins. Recycling of CD1d from the cell surface results in 
the localization of CD1d to these endosomal/lysosomal compartments (figure 
1) where the lipids loaded on CD1d can be exchanged, and GSL loaded onto 
CD1d.  Finally, the GSLs are broken down to their individual components 
and are available to be reprocessed. The degradation products of GSLs can be 
recycled to ER-Golgi for reuse. Defects in GSL catabolism can have large 
impact and influence several biological functions, which is clearly seen in a 
number of inherited metabolic disorders caused by deficiency in GSL 
degrading enzymes within lysosomes. These diseases are called 
sphingolipidoses and fall into the group of lysosomal storage diseases (LSD). 
NKT cells are often severely affected in these situations, which may be 
explained by a direct effect resulting from the lack or accumulation of 
specific GSL, or an indirect effect caused by a general major disturbance in 
GSL homeostasis. The most common LSD is Gaucher disease [129] caused 
by deficiency in glucosylceramidase activity resulting in accumulation of 
GlcCer. Patients suffering from this disease can develop neurological 
damage, however, the majority of patients have a less severe outcome where 
accumulation of GlcCer is restricted to tissue macrophages, which cause 
hepatosplenomegaly, pancytopenia, and skeletal deterioration.  
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through the action of glucosylceramide synthase (GCS, see figure 5), 
synthesis of GlcCer occurs at the cytoplasmic face of ER as well as in early 
Golgi (cis) and subsequently flips into the Golgi lumen, where synthesis of 
more complex GSLs take place by a series of glucosyltransferases (the GSL 
series are shown in figure 5) (reviewed in [127]). These complex GSLs 
consist of α and β-linked glucose, galactose, N-acetylglucosamine, and/or N-
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of endosomes with lysosomes makes the GSLs available for cleavage into 
smaller structures, by lysosomal hydrolases with the help from activator 
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Figure 6. Intracellular pathways of GSL biosynthesis. Biosynthesis of GSL 
starts in ER and Golgi where different carbohydrates are added to ceramide by 
different GSL synthases. Thereafter, the GSLs are transported via vesicles to the 
plasma membrane. Through invaginated vesicles, GSLs internalize into 
endosomes where after fusion with lysosomes occur. In lysosomes, GSLs are 
cleaved into smaller structures and are available to be reprocessed.  
Sulfatide 
The GSL sulfatide is formed in Golgi by the action of cerebroside 
sulfotransferase (CST, see figure 5 and 6) catalyzes the addition of a sulfate 
group in 3-position of GalCer to form sulfatide. The GSL sulfatide is a 
naturally existing GSL in several mammalian tissues such as CNS, 
gastrointestinal tract, kidneys and pancreas. In these organs, the fatty acid 
chain of sulfatide varies in length and degree of saturation. In CNS, sulfatide 
consists mainly of isoforms with long unsaturated fatty acids such as C24:1, 
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while isoforms in pancreas are dominated by shorter saturated fatty acids 
such as C16:0 (see structures in figure 7A-B) [130, 131]. This indicates that 
different isoforms of sulfatide might have different functions in distinct 
tissues. Studies have shown that sulfatide co-localizes with insulin within 
pancreatic β-cells and are believed to stabilize the insulin crystals within the 
granules of the beta cells and furthermore facilitate the release of insulin 
[132]. In CNS, sulfatide has important functions in the myelin sheath such as 
in the development of paranodal junctions [133]. In metachromatic 
leukodystrophy the enzyme arylsulfatase A (ASA, see figure 5), which 
degrades sulfatide, is deficient and leading to the accumulation of sulfatide 
and lyso-sulfatide in lysosomes of various tissues. This leads to 
demyelination and neurological deterioration (reviewed in [134]). The lyso-
form of sulfatide lacking the fatty acid chain, lyso-sulfatide, (figure 7C) also 
exists naturally but at low levels, however lyso-sulfatide, as well as other 
lyso-GSLs are increased in lysosomal storage diseases [135-140].   
ER
Nucleus
Lysosome
Endosome
cis
Golgi
trans
CERT
Ceramide GalCer
GlcCer Sulfatide
Hydrolases
Saposins
Cytoplasma
Extracellular
SM
Introduction 
28 
 
Figure 6. Intracellular pathways of GSL biosynthesis. Biosynthesis of GSL 
starts in ER and Golgi where different carbohydrates are added to ceramide by 
different GSL synthases. Thereafter, the GSLs are transported via vesicles to the 
plasma membrane. Through invaginated vesicles, GSLs internalize into 
endosomes where after fusion with lysosomes occur. In lysosomes, GSLs are 
cleaved into smaller structures and are available to be reprocessed.  
Sulfatide 
The GSL sulfatide is formed in Golgi by the action of cerebroside 
sulfotransferase (CST, see figure 5 and 6) catalyzes the addition of a sulfate 
group in 3-position of GalCer to form sulfatide. The GSL sulfatide is a 
naturally existing GSL in several mammalian tissues such as CNS, 
gastrointestinal tract, kidneys and pancreas. In these organs, the fatty acid 
chain of sulfatide varies in length and degree of saturation. In CNS, sulfatide 
consists mainly of isoforms with long unsaturated fatty acids such as C24:1, 
Introduction 
29 
while isoforms in pancreas are dominated by shorter saturated fatty acids 
such as C16:0 (see structures in figure 7A-B) [130, 131]. This indicates that 
different isoforms of sulfatide might have different functions in distinct 
tissues. Studies have shown that sulfatide co-localizes with insulin within 
pancreatic β-cells and are believed to stabilize the insulin crystals within the 
granules of the beta cells and furthermore facilitate the release of insulin 
[132]. In CNS, sulfatide has important functions in the myelin sheath such as 
in the development of paranodal junctions [133]. In metachromatic 
leukodystrophy the enzyme arylsulfatase A (ASA, see figure 5), which 
degrades sulfatide, is deficient and leading to the accumulation of sulfatide 
and lyso-sulfatide in lysosomes of various tissues. This leads to 
demyelination and neurological deterioration (reviewed in [134]). The lyso-
form of sulfatide lacking the fatty acid chain, lyso-sulfatide, (figure 7C) also 
exists naturally but at low levels, however lyso-sulfatide, as well as other 
lyso-GSLs are increased in lysosomal storage diseases [135-140].   
Introduction 
30 
Figure 7. Naturally excisting sulfatide isoforms. Semi-synthetic sulfatide 
isoforms with d18:1 sphingosine (1,3-dihydroxy-2-aminooctadecene) and fatty 
acid chain of (A) C24:1, (B) C16:0 and (C) without fatty acid chain (lyso), 
synthesized from native sulfatide.  
NKT cell functions 
The unique functions of NKT cells 
NKT cells are functionally different from conventional MHC restricted T 
cells in terms of their activation state. NKT cells have an activated memory 
phenotype with high expression of CD44 and the IL-2 receptor β (CD122) in 
contrast to the naïve phenotype of conventional T cells. During an immune 
response NKT cells are rapidly activated, indicated by a fast production of 
high amounts of cytokines, including IFN-γ, IL-4, IL-10, IL-13, IL-17, IL-21 
and tumor necrosis factor (TNF) [38, 46, 72, 141-143]. The type of cytokine 
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profile produced depends on signals, such as IL-12, obtained during 
activation.  
When activated, NKT cells can promote or suppress the immune system 
(reviewed in [74, 144]). By comparing wild type mice with mice deficient in 
type I NKT cells (J281-/-), or mice deficient in all NKT cells (CD1d-/-), it has 
been possible to study the natural role of type I and type II NKT cells in 
several immune settings. Collectively, these studies have demonstrated that 
type I and type II NKT cells seem to have similar functions in some settings, 
however in other situations they can counteract as well as regulate each other 
[145, 146]. This demonstrates that the two subpopulations of NKT cells can 
have very different functions in immunity. Further, in vivo targeting of NKT 
cells by administration of activating lipid ligands such as α-GalCer has 
demonstrated the potent regulatory ability of activated NKT cells [91]. 
Structural variants of α-GalCer have been developed that activate type I NKT 
cells and bias the immune response in either a Th1 or Th2 direction 
depending on the modification. This demonstrates the importance of studying 
the role of different lipid isoforms, as small changes in structure, such as the 
length and saturation of the fatty acid chain, can have a great impact on the 
outcome of the immune response [94, 98].  
NKT cells in autoimmunity 
NKT cells have been linked to several autoimmune diseases, however the 
role of NKT cells in autoimmune diseases has not always been associated 
with beneficial effects. In some autoimmune setting, they may also have a 
pathogenic role. In patients with rheumatoid arthritis, numbers of type I NKT 
cells were decreased in peripheral blood and synovium [147-149] and it was 
suggested that low numbers of NKT cells contribute to the development of 
rheumatoid arthritis. A pathogenic role for NKT cells was established using a 
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rheumatoid arthritis. A pathogenic role for NKT cells was established using a 
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mouse model for rheumatoid arthritis, in which the disease is induced by 
immunization with heterologous type-II collagen. Mice lacking type I NKT 
cells have less severe rheumatoid arthritis compared to control mice [150], 
and the lack of type I NKT cells resulted in a Th2 bias, which was beneficial 
for protection [151]. In MS, decreased numbers of type I NKT cells in 
peripheral blood of patients has been demonstrated. Interestingly, this 
reduction seems to correlate with relapse of the disease [152-154], while 
numbers of type I NKT cells were increased during the remission phase 
[155]. Further, an induced activation of either type I or type II NKT cells by 
the administration of activating lipid ligands has been shown to influence the 
development of the mouse model of MS [156-158]. Sulfatide administration 
at the induction of EAE protected the mice from developing the disease in a 
CD1d dependent manner. The protection was associated with lower levels of 
IFN-γ and IL-4 produced by autoantigen reactive T cells. In systemic lupus 
erythematosus (SLE), where an impaired clearance of apoptotic cells gives 
rise to development of autoantibodies, NKT cells have been suggested to 
have an important protective role. Mice that spontaneously develop 
autoantibodies and nephritis (NZB/NZW F1 mice) and were deficient in 
NKT cells have more severe nephritis [159]. Further, old Jα18-/- mice, 
deficient in type I NKT cells, spontaneously develop a SLE like syndrome 
with production of antibodies against double stranded DNA and proteinuria 
[160], indicating that NKT cells can regulate the production of autoantibodies 
towards apoptotic cells. In 2010, Wermeling et al demonstrated that type I 
NKT cells have a suppressive role in the development of autoantobodies 
against an increased load of apoptotic cells in the circulation. The protective 
effect seen by type I NKT cells was through a cognate interaction between 
NKT cells and CD1d expressing B cells [161].  
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Type II NKT cells in experimental autoimmune 
encephalomyelitis  
In MS and its mouse model EAE, the myelin sheath in CNS is the target for 
an autoimmune inflammatory process [162], which consequently leads to 
degradation of the myelin sheath accompanied by neurological problems and 
paralysis. Sulfatide is highly abundant in CNS; approximately 20% of all 
galactolipids in CNS are sulfatide, which indicates its importance in this 
organ. Interestingly, circulating T cells reactive towards GSL are more 
frequent in MS patients than control donors [163]. Among those GSLs are 
sulfatide, which suggests that glycolipids including sulfatide are released 
during the destruction of the myelin sheath and induce the activation of 
immune cells. It was demonstrated that these GSL reactive T cells were 
producers of proinflammatory cytokines such as TNF-α and IFN-γ, and it 
was suggested that they might promote, rather than control the 
autoinflammatory process in the CNS. Later, Jahng et al demonstrated that 
CD1d restricted type II NKT cells were activated by sulfatide in vitro, and 
that sulfatide reactive cells accumulate in CNS during the process of 
demyelination in EAE. These CNS infiltrating sulfatide reactive type II NKT 
cells produced IFN-γ but not IL-4. Interestingly, sulfatide administration 
completely protected mice from developing EAE in a CD1d-dependent 
manner, suggesting that the protective effect of sulfatide was mediated 
through CD1d-restricted NKT cells. Injection of sulfatide reduced the 
production of IFN-γ and IL-4 by autoantigen reactive T cells indicating a 
dampened activation of autoagressive cells. Subsequent studies investigating 
the role of IFN-γ in EAE have shown that IL-17, rather than IFN-γ plays a 
role in the pathogenesis. Notably, IFN-γ counteracts IL-17 production. This 
might explain how IFN-γ producing type II NKT cells could have a 
protective role in EAE [164].  
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The immunomodulatory role of sulfatide in vivo 
Since the discovery that sulfatide activates immunomodulatory type II NKT 
cells in EAE, sulfatide administration has been used in several immune 
setting in an attempt to modify immunity. In addition to its effects in EAE, 
sulfatide has been demonstrated to suppress tumor immunity resulting in 
increased tumor growth. In contrast, in the same tumor model, administration 
of α-GalCer was protective. When type I and type II NKT cells were 
simultaneously activated by α-GalCer and sulfatide, type II NKT cells 
suppressed the protective effect by type I NKT cells [145], suggesting that 
type II NKT cells could down modulate both tumor immunity and type I 
NKT cells when activated by ligand. In concanavalin A induced hepatitis, 
where type I NKT cells play an important role in mediating the disease, 
sulfatide administration mediated protection by the induction of anergy in 
type I NKT cells [146].  ConA induced hepatitis results in the infiltration of 
neutrophils and a cytokine burst in the liver, but after sulfatide treatment this 
did not take place due to the anergy of type I NKT cells. In hepatic ischemic 
reperfusion injury, the protective effect induced by sulfatide was associated 
with reduced IFN-γ production by pathogenic type I NKT cells and reduced 
hepatic recruitment of myeloid subsets, which normally occur during hepatic 
ischemic reperfusion injury [165]. Further, it has also been shown that 
sulfatide inhibits human immunodeficiency virus (HIV) replication in mice 
[166]. Virus replication was lowered significantly up to 4-8 weeks post 
infection. Altogether, this suggests that sulfatide, through its activation of 
sulfatide reactive type II NKT cells has strong immunomodulatory capacity.  
Type 1 diabetes 
Autoimmune type 1 diabetes (T1D) is caused by a T cell mediated 
destruction of insulin producing β-cells in the pancreatic islets of Langerhans. 
Animal models, such as the non-obese diabetic (NOD) mouse [167], that 
Introduction 
35 
spontaneously develops T1D similar to the human disease have provided 
successful tools to study the mechanisms involved in the disease 
pathogenesis. In NOD mice, diabetes develops in two stages which involves 
an initial phase where cells infiltrate the pancreas without destruction of β-
cells, followed by a second phase when the infiltrating cells start to destroy 
β-cells (reviewed in [168]). In the NOD model, it is well established that 
different types of regulatory cells control the onset and progression of T1D. 
This was illustrated by crossing mice with a transgenic TCR (BDC2.5 NOD 
[169, 170]) specific for a pancreatic peptide, to mice lacking the ability of 
rearrange T and B cell receptors. TCR transgenic mice that lacked 
endogenous T and B cell receptors developed an early and very rapidly 
progressing disease, caused by the absence of immunoregulation [170]. In 
addition, NKT cells were suggested to have a protective role in T1D when it 
was shown that NOD mice have impaired numbers and functions of type I 
NKT cells [171, 172]. Further, transfer of DN thymocytes, most likely 
containing a large fraction of NKT cells, to NOD mice prevented the onset of 
T1D [172]. Also type II NKT cells have been implied in T1D protection; 
over expression of a type II NKT cell TCR (Vα3.2+Vβ9+) in NOD mice 
almost completely prevented the onset of disease [173]. These cells produced 
high levels of IFN-γ and low levels of IL-4. In 2012, Kadri et al. 
demonstrated that CD4+, but not DN, TCR transgenic Vα3.2+Vβ9+ type II 
NKT cells efficiently down regulated T1D induced by BDC2.5 NOD T cells 
in adoptive transfer experiments, through a mechanism that was dependent on 
the inducible T-cell costimulator (ICOS) and programmed cell death 1 (PD-
1) pathways [174].  
Moreover, activation of type I NKT cells by α-GalCer protects NOD mice 
from developing T1D [175-178]. The most efficient protection was observed 
with repeated α-GalCer administrations for several weeks. When 
Introduction 
34 
The immunomodulatory role of sulfatide in vivo 
Since the discovery that sulfatide activates immunomodulatory type II NKT 
cells in EAE, sulfatide administration has been used in several immune 
setting in an attempt to modify immunity. In addition to its effects in EAE, 
sulfatide has been demonstrated to suppress tumor immunity resulting in 
increased tumor growth. In contrast, in the same tumor model, administration 
of α-GalCer was protective. When type I and type II NKT cells were 
simultaneously activated by α-GalCer and sulfatide, type II NKT cells 
suppressed the protective effect by type I NKT cells [145], suggesting that 
type II NKT cells could down modulate both tumor immunity and type I 
NKT cells when activated by ligand. In concanavalin A induced hepatitis, 
where type I NKT cells play an important role in mediating the disease, 
sulfatide administration mediated protection by the induction of anergy in 
type I NKT cells [146].  ConA induced hepatitis results in the infiltration of 
neutrophils and a cytokine burst in the liver, but after sulfatide treatment this 
did not take place due to the anergy of type I NKT cells. In hepatic ischemic 
reperfusion injury, the protective effect induced by sulfatide was associated 
with reduced IFN-γ production by pathogenic type I NKT cells and reduced 
hepatic recruitment of myeloid subsets, which normally occur during hepatic 
ischemic reperfusion injury [165]. Further, it has also been shown that 
sulfatide inhibits human immunodeficiency virus (HIV) replication in mice 
[166]. Virus replication was lowered significantly up to 4-8 weeks post 
infection. Altogether, this suggests that sulfatide, through its activation of 
sulfatide reactive type II NKT cells has strong immunomodulatory capacity.  
Type 1 diabetes 
Autoimmune type 1 diabetes (T1D) is caused by a T cell mediated 
destruction of insulin producing β-cells in the pancreatic islets of Langerhans. 
Animal models, such as the non-obese diabetic (NOD) mouse [167], that 
Introduction 
35 
spontaneously develops T1D similar to the human disease have provided 
successful tools to study the mechanisms involved in the disease 
pathogenesis. In NOD mice, diabetes develops in two stages which involves 
an initial phase where cells infiltrate the pancreas without destruction of β-
cells, followed by a second phase when the infiltrating cells start to destroy 
β-cells (reviewed in [168]). In the NOD model, it is well established that 
different types of regulatory cells control the onset and progression of T1D. 
This was illustrated by crossing mice with a transgenic TCR (BDC2.5 NOD 
[169, 170]) specific for a pancreatic peptide, to mice lacking the ability of 
rearrange T and B cell receptors. TCR transgenic mice that lacked 
endogenous T and B cell receptors developed an early and very rapidly 
progressing disease, caused by the absence of immunoregulation [170]. In 
addition, NKT cells were suggested to have a protective role in T1D when it 
was shown that NOD mice have impaired numbers and functions of type I 
NKT cells [171, 172]. Further, transfer of DN thymocytes, most likely 
containing a large fraction of NKT cells, to NOD mice prevented the onset of 
T1D [172]. Also type II NKT cells have been implied in T1D protection; 
over expression of a type II NKT cell TCR (Vα3.2+Vβ9+) in NOD mice 
almost completely prevented the onset of disease [173]. These cells produced 
high levels of IFN-γ and low levels of IL-4. In 2012, Kadri et al. 
demonstrated that CD4+, but not DN, TCR transgenic Vα3.2+Vβ9+ type II 
NKT cells efficiently down regulated T1D induced by BDC2.5 NOD T cells 
in adoptive transfer experiments, through a mechanism that was dependent on 
the inducible T-cell costimulator (ICOS) and programmed cell death 1 (PD-
1) pathways [174].  
Moreover, activation of type I NKT cells by α-GalCer protects NOD mice 
from developing T1D [175-178]. The most efficient protection was observed 
with repeated α-GalCer administrations for several weeks. When 
Introduction 
36 
administering an analog of α-GalCer (OCH), with a truncated sphingosine 
chain, which gives rise to reduced levels of IFN-γ and high levels of IL-4 
after stimulation of type I NKT cells, a more effective protection against T1D 
in NOD mice was observed compared to α-GalCer treatment [179]. This 
confirms that minor changes in structures of lipid antigens may cause great 
differences in terms of the activation and induced effector functions of NKT 
cells [180].  
It is interesting to note that the type II NKT cell ligand sulfatide is present in 
β-cells of the pancreatic islets. Since T1D is an autoimmune disease where a 
specific destruction of pancreatic β-cells occurs, it seems possible that upon 
destruction, β-cell associated GSLs such as sulfatide may be released and 
induce an immune response, similar to what has been shown in MS and EAE 
[163]. Notably, it is known that human patients with T1D, but not healthy 
individuals, have autoantibodies against sulfatide in serum [88], supporting 
this concept. These findings prompted our studies of the possible role of 
sulfatide reactive NKT cells in T1D.  
NKT cells in infections 
Due to the rapid production of high amounts of inflammatory cytokines, 
NKT cells possess a powerful capacity to enhance immunity against several 
infections. In murine models, NKT cells have been described to induce 
immunity to several pathogens such as viruses, gram-positive bacteria, gram-
negative bacteria, fungi, parasites and helminths [181]. In 2000, Kumar et al 
demonstrated that Borrelia burgdorferi (Bb) infected CD1d-/- mice showed 
increased Bb specific IgG antibodies and developed infection induced 
arthritis, suggesting that NKT cells play a role in the protection from Bb 
infection in mice [182]. NKT cells can polarize conventional CD4+ T cells 
into either Th1 or Th2 and thereby modulate the immune system to several 
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microbial infections, including bacteria and helminths. NKT cells might also 
have negative effects such as causing increased liver injury during 
Salmonella infection [183]. In Pseudomonas aeruginosa and Streptococcus 
pneumoniae lung infections, type I NKT cells have been shown to induce 
protection in mice. Protection was associated with recruitment of type I NKT 
cells to the site of infection that subsequently promoted the recruitment of 
neutrophils. Moreover, activation of type I NKT cells by administration of α-
GalCer inhibited hepatitis B virus (HBV) replication in the liver of HBV 
transgenic mice. The inhibition induced by α-GalCer was associated with 
induction of IFN-γ and IFN-α/β in the liver [184]. In addition, type II NKT 
cells have also been shown to play a role in the defence to HBV infection, 
using the same transgenic model [185]. The first insight concerning a role for 
type II NKT cells during infections was obtained from studies of mice 
infected with diabetogenic encephalomyocarditis virus (EMCV-D). A 
protective effect was observed both by type I and type II NKT cells [186]. 
Using Jα18-/-, CD1d-/- and C57BL/6 (wildtype (WT)) mice, it was 
demonstrated that during infection with the parasite Trypanosoma cruzi, type 
II NKT cells increased the anti-parasite response while type I NKT cells 
limited the response. Type I NKT cell deficient Jα18-/- mice developed 
increased weight loss and mortality as well as an augmented splenomegaly 
compared to CD1d-/- and WT mice [187]. This suggests that type I and type II 
NKT cells may perform different immunological functions in immunity 
against infections. A divergent function of type I and II NKT cells was also 
observed during helminth infection by Schistosoma mansoni where type I 
NKT cells promoted a Th1 cell differentiation whereas type II NKT cells 
provided help for a Th2 cellular response. Recently, HBV infection has been 
demonstrated to induce the activation of type II NKT cells by a CD1d-
dependent recognition of HBV induced lyso-phospholipids derived from ER 
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[120]. Subsequently to activation of type II NKT cells, an IL-12–mediated 
indirect activation of type I NKT cells occurred. The absence of NKT cells or 
ER-associated transfer of lipids onto CD1d diminished the HBV infection, 
suggesting that NKT participate in the viral control by recognition of lyso-
phospholipids.  
NKT cells in sepsis 
The occurrence of systemic bacterial infection is the foremost health problem 
leading to deaths in hospital care units worldwide [188]. One major 
bacterium causing sepsis is the gram-positive Staphylococcus aureus (S. 
aureus) [189]. The hallmarks of sepsis consist of an initial hyperreactive 
phase with excessive inflammation, followed by a anti-
inflammatory/immunosupressed, latent phase [190]. During the initial phase, 
after systemic exposure to bacteria, there is a massive release of pro-
inflammatory cytokines such as TNF, IL-1, IL-6 and IFN-γ from circulating 
activated monocytes, macrophages and other immune cells. In a mouse 
model for sepsis, injection of the endotoxin LPS into mice causes a lethal 
chock syndrome that is mediated by IL-12 and subsequent IFN-γ production, 
followed by the production of pro-inflammatory cytokines such as TNF-α 
and IL-1 and other inflammatory mediators [191-193]. APC derived IL-12 
induces the activation of NKT cells, which rapidly produce high amounts of 
IFN-γ [194], as well as increase their cytotoxicity in the liver [195]. In the 
absence of NKT cells, the mortality after a lethal dose of LPS was 
significantly reduced [196]. Mice deficient in type I NKT cells (Jα18-/-) had 
significant survival advantages with reduced serum concentrations of IFN-γ 
and TNF-α compared to wild type controls, suggesting that type I NKT cells 
play a role in the initiation of septic shock induced by LPS. However, 
administration of α-GalCer before or shortly after LPS challenge reduced 
sepsis in these mice [197]. Interestingly, protected mice showed decreased 
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frequencies of NKT cells expressing IFN-γ and higher frequencies expressing 
IL-10 suggesting that ligand mediated modulation of NKT cells in this 
situation resulted in a shift towards a protective response. Even though type I 
NKT cells have pathogenic effects in the LPS model of severe sepsis, they 
may have beneficial functions in less severe sepsis-like situations, such as 
endotoxemia and microbial infections, by contributing to increased clearance 
of pathogens [198]. To achieve a balance between a proper and robust 
inflammatory response resulting in an efficient clearance of bacteria without 
overstimulation and subsequent septic shock is of major concern in the 
treatment of sepsis.  
NKT cells in tumor immunity 
α-GalCer was first discovered as a potent antitumor agent, and the role of 
NKT cells in tumor immunity was revealed when α-GalCer was found to 
activate type I NKT cells, a requirement for the antitumor activity [99]. 
Further, IL-12 was known to possess antitumor properties [199] but the 
downstream effects of IL-12 was not described. Through the use of Jα18-/- 
mice, Cui et al were able to demonstrate the significant effect of type I NKT 
cells in antitumor immunity driven by IL-12 [200], dependent on a direct 
contact between type I NKT cells and tumor cells. Additionally, activating 
type I NKT cells by α-GalCer resulted in type I NKT cell mediated killing of 
tumor cells through a CD1d-independent, NK-like mechanism [201]. 
Moreover, an antitumor function of type I NKT cells in the absence of 
exogenously administered stimulators such as IL-12 or α-GalCer has been 
described [144] using the chemical carcinogen methylcholanthrene (MCA) 
that induces tumor formation. Here, the protective activity was depending on 
IFN-γ production by NKT cells and subsequently the activation of NK cells, 
while perforin expression on NKT cells was not required. Furthermore, it was 
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demonstrated that DN and not CD4+ NKT cells derived from liver, but not 
spleen or thymus, mediated the protective activity.  
While type I NKT cells have been described to possess a protective role in 
tumor immunity, type II NKT cells can give rise to opposite effects [202] 
[145]. In different tumor models, Jα18-/- mice have been demonstrated to 
have an accelerated tumor growth compared to CD1d-/- mice, suggesting that 
type II NKT cells reduce tumor immunity while type I NKT cells promote it. 
A series of studies demonstrated that CD4+ type II NKT cells suppressed 
antitumor CD8+ T cells by the production of IL-13, that in turn induced 
secretion of TGF-β by myeloid cells, resulting in increased tumor growth 
[145].  In addition, it was shown in two different tumor models, in line with 
previous data, that α-GalCer administration enhanced tumor immunity and 
protected mice, while sulfatide administration activated type II NKT cells 
that suppressed tumor immunosurveillance resulting in increased tumor 
growth [145].  
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Innate-like lymphocytes, such as NKT cells have unique characteristics and 
regulatory functions in the immune system. They are autoreactive cells that 
have an activated memory phenotype, which makes them respond rapidly and 
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aims of this thesis were to expand the knowledge on how to activate type II 
NKT cells as well as to evaluate their immunoregulatory function in 
autoimmunity and infection. 
Specific aims 
1. To evaluate the activation of type II NKT cells by the 
glycosphingolipid sulfatide and to determine the role of 
sulfatide in the autoreactivity of type II NKT cells 
 
2. Indentify self-lipids that are involved in the autoreactivity of 
type II NKT cells 
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type 1 diabetes development through the induction of 
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KEY METHODOLOGY 
Cells 
For analyzing sulfatide reactivity and autoreactivity of type II NKT cells, the 
type II NKT hybridoma XV19 was used [41]. These cells were generated 
from CD4+ T cells from MHCII-/- mice and were initially identified as CD1d-
autoreactive, and later demonstrated to be sulfatide reactive CD1d restricted 
type II NKT cells [30]. T cell hybridomas are generated by fusion of antigen-
specific T cells with a tumor cell, usually a thymoma. Properties of the tumor 
fusion partner are inherited, which means that T cell hybridomas constantly 
divide, however they do not retain functions of the original primary T cells. 
Of importance, T cell hybridomas are generally less dependent than primary 
cells to co-stimulation for activation, and are commonly used for detailed 
studies of antigen reactivity [203]. When activated by antigens, presented on 
APCs, T cell hybridomas produce IL-2. The IL-2 production produced is a 
direct correlation of the activation of the T cell hybridoma. As APCs for 
presentation of GSLs we have used the DC line, JawsII cells [204], unless 
otherwise stated. We found that JawsII cells are optimal APCs for our studies 
due to the fact that they naturally express high levels of CD1d, and efficiently 
present lipids on CD1d while they induce low levels of autoreactivity of 
XV19 cells. Further, to obtain physiologically relevant subsets of DCs, we 
cultured bone marrow (BM) cells in the presence of FLT3L, which is a 
growth factor that gives rise to the majority of mouse DC populations found 
in vivo [205, 206]. 
Glycosphingolipids 
Native sulfatide at a purity of >95% (determined by thin layer 
chromatography and mass spectometry) had been isolated from pig brain 
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[207]. Lyso and sulfatide isoforms containing the fatty acids of caprylic acid 
(C8:0), lauric acid (C12:0), palmitic acid (C16:0), oleic acid (C18:1), 
lignoceric acid (C24:0) and nervonic acid (C24:1) were produced from pig 
brain-derived native sulfatide [208]. The solubility in culture medium at final 
concentration of the various sulfatide isoforms was verified by thin layer 
chromatography in selected experiments, and was found to be >80%. Native 
GlcCer and GalCer, and production of their semi-synthetic isoforms have 
been described before [209]. The synthesized isoforms were free of 
detectable contaminations in the analysis by thin layer chromatography and 
mass spectometry, revealing a purity of >99%. Semi-synthetic lyso-
lactosylceramide, lyso-sphingomyelin, lyso-GM1 and lyso-
globotriaosylceramide were purchased from Matreya (PA, USA).  
Cellular lipid extracts and fractionation 
A20CD1d cells [107] give rise to very high autoreactivity of XV19 cells, and 
therefore we hypothesized that A20CD1d cells present potent stimulatory self 
lipids for XV19 cells. To identify stimulatory lipid ligands presented by 
A20CD1d cells we isolated cellular lipids and fractionated them into different 
lipid fractions, according to their solubility. It should be noted that when we 
started the project, GSLs were the main class of lipids known to stimulate 
NKT cells. The GSLs α-GalCer and iGb3 [99, 110] had been identified as 
stimulatory ligands for type I NKT cells and the GSL sulfatide for type II 
NKT cells [30]. Therefore we isolated lipids from A20CD1d according to 
protocols for purification of GSLs.  
T cell hybridoma assays 
We have used two different methods to evaluate the activation of XV19 cells 
by GSLs; APC-based assay and APC-free assay, where CD1d is bound to 
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plastic plates (plate-bound CD1d). These two methods are considerably 
different. Lipid loading onto CD1d in the APC assay can take place on the 
surface of the APC, but also through uptake and intracellular loading, 
therefore, several parameters in addition to the TCR-ligand-CD1d interaction 
will determine the ability of a certain lipid to stimulate an NKT cell. When 
using plate-bound CD1d, a direct loading of the lipid onto CD1d has to take 
place.  
IL-2 analysis 
CTLL-2 cells [210] or IL-2 ELISA were used as readouts for activation of 
XV19 cells, and subsequently produced IL-2. CTLL-2 cells are dependent on 
IL-2 for survival, thereby they can be used for analysis of IL-2 in supernatant 
from XV19 hybridoma assays. When using CTLL-2 cells as readout for IL-2 
production, XV19 hybridoma stimulation is measured by 3H-thymidine 
incorporation and therefore expressed as cpm determined in the CTLL assay. 
A titration of IL-2 was always included as reference to ensure that the 
responses were in the linear response range. During the course of the study, 
IL-2 ELISA became more frequently used to determine the activation of the 
T cell hybridomas. Because IL-2 ELISA provides a quantitative measurement 
of the amounts of IL-2 produced, we are now routinely using this method as 
readout for IL-2 production.  
Mice 
NOD mice are a commonly used mouse model to study T1D. NOD mice 
spontaneously develop T1D similar to the human disease, caused by the 
destruction of β-cells in the Langerhans islets of the pancreas [167]. In NOD 
mice, the T1D process starts as early as 2 weeks after birth when β-cells 
within pancreas experiences a wave of β-cell death, followed by presentation 
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of pancreas derived antigens in the draining pancreatic lymph nodes leading 
to the activation of autoagressive T cells. After 3-4 weeks, insulitis is 
initiated and an accumulation of immune cells take place in the pancreas. 
When approximately 80% of the islets have been destroyed and insulin 
production is too low to regulate blood glucose levels, clinical signs of 
diabetes occur, starting from around 12 weeks of age. At 25–30 weeks of age, 
around 80% of female NOD mice have become diabetic, but only 20–30% of 
the male mice become diabetic. The diabetes incidence may fluctuate to some 
degree due to different animal houses, depending how clean the environment 
is as well as other factors.   
Staphylococcal sepsis induction 
To evaluate the role of NKT cells in sepsis we have used S. aureus. 
Specifically, we have used the TSST-1 producing S. aureus LS-1 strain. The 
LS-1 strain was isolated from a spontaneously arthritic NZB/W mouse [211], 
and is a well established strain in for studies of staphylococcal sepsis and 
arthritis in mice [212, 213].  
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RESULTS AND DISCUSSION 
The activation of type II NKT cells by 
naturally existing GSLs 
Physiological isoforms of sulfatide stimulate type 
II NKT cells (Paper I) 
After the discovery of type II NKT cells in 1995 [41], the activation and 
functional ability of the cells were not well known for several years. Almost a 
decade later, the self-lipid sulfatide was identified as a stimulatory lipid 
ligand for type II NKT cells [30]. Notably, sulfatide is highly abundant in 
pancreas and CNS [130, 131], where sulfatide has important functions. In 
CNS, sulfatide is critical for the maintenance of the myelin sheath and axon 
structure [214]. Mice deficient in CST (see figure 5) and thereby lacking 
sulfatide develop neurological abnormalities as well as defects in 
spermatogenesis, which results in paralysis and sterility [133]. In pancreas, 
sulfatide is believed to be involved in the release of insulin by stabilizing 
insulin crystals within the granules of the β-cells [132]. Further, in these 
organs, sulfatide exists in different isoforms. The main isoforms of sulfatide 
in CNS have long unsaturated, such as C24:1, and saturated, such as C24:0, 
fatty acids [132]. In pancreas, sulfatide exists in isoforms with saturated fatty 
acids. The short fatty acid (C16:0) isoform comprises one and the longer 24 
carbon atom (C24:0) the other major species in islets [132, 215]. Notably, in 
MS or T1D, myelin proteins in CNS or pancreatic β-cells are targets for 
destruction by autoaggressive cells [162], suggesting that during the tissue 
destruction phase of these autoimmune diseases, sulfatide may be released 
from these tissues and subsequently activate type II NKT cells (figure 3E). 
Interestingly, T cells reactive to myelin GSLs are increased in peripheral 
blood of patients with MS [163]. Further, native sulfatide extracted from 
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the male mice become diabetic. The diabetes incidence may fluctuate to some 
degree due to different animal houses, depending how clean the environment 
is as well as other factors.   
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RESULTS AND DISCUSSION 
The activation of type II NKT cells by 
naturally existing GSLs 
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destruction phase of these autoimmune diseases, sulfatide may be released 
from these tissues and subsequently activate type II NKT cells (figure 3E). 
Interestingly, T cells reactive to myelin GSLs are increased in peripheral 
blood of patients with MS [163]. Further, native sulfatide extracted from 
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bovine brain, administered simultaneously with EAE induction completely 
protects mice from developing EAE in a CD1d dependent manner [30], 
indicating an induced protective role of sulfatide reactive type II NKT cells in 
EAE. Altogether this suggests that a fraction of type II NKT cells are 
activated by sulfatide in these diseases and that these sulfatide reactive cells 
may possess immunoregulatory properties. Due to the fact that sulfatide 
exists naturally in different isoforms in certain organs, we sought to 
determine whether sulfatide reactive type II NKT cells are differently 
activated by these tissue specific isoforms.  
When using the sulfatide reactive, CD1d restricted type II NKT cell 
hybridoma XV19 [41] to study the stimulatory capacity of sulfatide isoforms 
we found that sulfatide without fatty acid chain (lyso) has the greatest 
capacity of activating XV19 cells, followed by 
C24:1>C24:0>C12>C16:0>/=C18:1 isoforms (figure 8). The activation of 
XV19 cells by C24:1, C24:0 and C16:0 sulfatide isoforms indicates that 
indeed the type II NKT cells are activated by sulfatide isoforms known to 
exist in different mammalian tissues such as CNS and pancreas, during 
normal conditions. Interestingly, semi-synthetic isoforms with short fatty acid 
chains (C8 and C12) and C18:1, that are not known to exist naturally, only 
weakly or moderately stimulated XV19 cells. Also, in addition to XV19 cells, 
two additional type II NKT cell hybridomas are activated by sulfatide, 
14S.15.5D [108] (figure 4, paper I) and IC8.DC1 [6], which suggest that the 
recognition of sulfatide may be a common reactivity of type II NKT cells. 
Interestingly, the TCR gene segments used by XV19 [216] and 14S.15.5D 
[108] cells are different, suggesting that even though type II NKT cells 
express diverse TCR, some type II NKT cells can recognize the same lipid 
antigen [217]. Altogether, this suggests that type II NKT cells are efficiently 
activated by sulfatide isoforms known to exist in different organs, suggesting 
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that sulfatide reactive type II NKT cells may have a natural role in 
autoimmune diseases related to tissue destruction of these sulfatide 
containing organs, such as CNS and pancreas.  
 
Figure 8. Sulfatide isoforms activate XV19 cells. (A) 30 nmol/ml or (B) 50 
nmol/ml of indicated sulfatide isoforms where added together with JawsII cells as 
APCs for 3-4 h before addition of XV19 cells, followed by incubation over night. 
IL-2 produced by XV19 cells was analyzed by CTLL-2 assay. (-) Indicate without 
lipid in culture  
In 2012, Patel and colleagues presented the crystal structure of CD1d bound 
to C24:1 sulfatide in association with the XV19 TCR [216]. The TCR of 
XV19 cells was cloned and sequenced and identified as Vα1-Jα26/Vβ16. In 
contrast to the parallel docking mode over the F´ pocket of type I NKT cell 
the Vα14–Jα18 TCR, the TCR of XV19 cells binds orthogonally above the 
A´ pocket of CD1d. Further, the XV19 TCR contact with CD1d:C24:1 
sulfatide was dominated by non germline encoded residues, where the 
CDR3α loop makes contacts with CD1d and the CDR3β loop shapes the 
specificity for sulfatide. This is in contrast to type I NKT cell TCR 
recognition of CD1d:α-GalCer, where interactions are dominated by 
germline encoded segments within the invariant Vα-Jα chain and the Vβ 
chain. Notably, some degree of conservation of the CDR3β loop of type II 
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NKT cells TCR has been observed among sulfatide reactive type II NKT cell 
TCRs, indicating common interactions for type II NKT cells with sulfatide 
and possibly other β-linked lipid antigens [217].  
Novel lipid ligands identified for XV19 type II NKT 
cells (Paper II) 
The fact that different APCs give rise to different degree of autoreactivty of 
XV19 cells indicates that this might be due to presentation of more or less 
stimulatory lipid ligands. Therefore we fractionated APCs that induce 
significantly high autoreactictivity of XV19 cells (figure 1B, paper II) and 
indeed, we could identify stimulatory lipid fractions that stimulate XV19 
cells. Mass spectometry demonstrated that the neutral GSL, β-GlcCer 
(GlcCer) with fatty acid chain lengths of C16:0 and C24:0 were dominating 
lipid species within the active fraction (figure 2E, paper II). When using 
semi-synthetic variants of C24:0 and C16:0 GlcCer we were able to 
demonstrate a CD1d dependent activation of XV19 cells by these isoforms 
(figure 3, paper II). In addition to GlcCer, we could demonstrate that the 
structurally similar β-GalCer (GalCer), which is the precursor to sulfatide, 
also stimulates XV19 cells (figure 4, paper II). The relative activation pattern 
by different isoforms of GlcCer and GalCer were similar to sulfatide (see 
structures in figure 9), where lyso-forms give rise to superior activation, 
followed by saturated or unsaturated C24 length of the fatty acid chain, 
however, the stimulation of XV19 cells is greater when using sulfated GalCer 
(sulfatide) compared to GlcCer and GalCer. This indicates that differences in 
positioning of the OH-group of the hexose has no importance for activation 
of XV19 cells, however sulfated galactose gives rise to increased activation, 
suggesting that the sulfate group enhances the interaction between CD1d-
lipid-TCR. The crystal structure of XV19 TCR to CD1d:C24:1 sulfatide 
reveal that the sulfate moiety form contact with TCR, however it did not form 
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any intricate hydrogen-bonding network [216]. From this, it was suggested 
that the sulfate moiety does not enhance the interaction between CD1d-lipid-
TCR, however further analysis are required. Further, the absence of 
stimulation of XV19 cells by lyso-sphingomyelin, lyso-
monosialotetrahexosylganglioside and lyso-lactosylceramide demonstrates 
that the activation by lyso-forms was not a general feature of GSL lyso-
forms, but appeared specific for sulfatide, GlcCer and GalCer (figure 4A, 
paper II). Interestingly, lyso-sulfatide is normally not present in high amounts 
in mammalian tissues, however it has been shown that patients suffering from 
the lysosomal storage disease metachromatic leukodystrophy have higher 
levels of lyso-sulfatide in the brain [218]. Further, lyso-sulfatide, along with 
other lyso-GSLs bound to high density lipoproteins (HDL) have been 
associated with reduced inflammation in the development of arteriosclerosis 
[219]. Lyso-GSLs:HDL binding to its receptor induce cellular signaling and 
retstriction of inflammation such as inhibition of NFkB. Interestingly, several 
other studies also demonstrate that lyso-compounds are highly stimulatory 
for NKT cells (see [220]), indicating that NKT cells can be activated in 
situations where you have accuulation of lyso-GSLs, including sulfatide. 
However, whether this does occur needs to be investigated.  
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Figure 9. Structure of stimulatory GSLs for type II NKT cells. GSL isoforms 
with d18:1 sphingosine (1,3-dihydroxy-2-aminooctadecene) with saturated or 
unsaturated fatty acid chains of C24. (A) C24:1 sulfatide, (B) C24:1 GalCer and 
(C) C24:0 GlcCer.  
Further, it is possible that increased stimulation of XV19 cells with lyso-
GSLs compared to C24 isoforms in the in vitro assays might be due to that 
lyso-compounds are less hydrophobic, as they lack the fatty acid chain. This 
increases the polarity and solubility, which may lead to increased 
accessibility of lyso-GSLs for loading on CD1d molecules and thereby 
enhance the activation of XV19 cells. However, this scenario may not be 
valid in vivo, where CD1d-mediated presentation of lyso-GSLs will be 
affected by additional factors. Notably, transport of lipids by lipid binding 
proteins in serum, and binding of these proteins to cellular receptors and 
uptake is suggested to significantly affect the presentation of lipid ligands on 
CD1d [221]. Apolipoprotein E (apoE) associated with very-low-density 
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lipoprotein (VLDL) has been demonstrated to target di-GalCer for uptake via 
the LDL receptor, which results in delivery to lysosomes and subsequent 
processing and loading onto CD1d for presentation. Interestingly, this 
pathway seems dispensable for presentation of α-GalCer [222], indicating 
that different lipids require distinct transport mechanisms in serum to achieve 
optimal uptake by APCs followed by presentation on CD1d in vivo.  
Notably, in addition to the docking mode of the XV19 TCR to CD1d loaded 
with C24:1 sulfatide, the molecular interaction of the XV19 TCR with CD1d 
and lyso-sulfatide was also recently solved. A comparison demonstrates 
remarkable similarities in XV19 TCR interaction with CD1d and exposed 
ligand, even though these two isoforms of sulfatide are structurally 
significantly different [216] [223]. Also, the affinity of XV19 TCR for 
CD1d:C24:1 was higher than for CD1d:lyso-sulfatide. This suggests that 
differences in the molecular recognition and affinity of this type II NKT cell 
TCR to CD1d:lyso-sulfatide does not explain the increased activation of type 
II NKT cells by lyso-sulfatide in comparison to C24:1 sulfatide. Further, 
when using an APC-free assay where CD1d is coated on plastic plates, we 
observed strong activation of XV19 cells by the lyso-forms and C24 length of 
the acyl chain of sulfatide, GlcCer and GalCer (figure 5, paper II), 
demonstrating that the increased activation of XV19 cells in the APC assay 
was not due to more efficient uptake and loading on CD1d by the lyso-GSLs. 
In addition, this also establishes that stimulation with lyso-GSL was not due 
to induction of co-stimulation or other non-specific factors in the APC. 
Whether there are biological consequences, such as biased cytokine 
production, which has been described with the use of different α-GalCer 
analoges [224-226], induced specifically by lyso-sulf, GlcCer and GalCer and 
other stimulatory lyso-compounds needs to be addressed.   
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The role of GSLs in the autoreactivity of type 
II NKT cells (Paper I and II) 
The autoreactivity is a hallmark for NKT cells and the role and identity of 
CD1d-presented ligands in this interaction have been extensively studied 
lately. Not only in the context of how NKT cells are selected by CD1d-
ligands, but also for the fact that NKT cell autoreactivity seems to be altered 
during immune responses such as to infections. Importantly, the selection of 
NKT cells in the thymus requires CD1d presentation of self-lipids [63, 227]. 
As for today, the self-lipids involved in the thymic positive selection of NKT 
cells are not fully known. Further, the identity of the self-lipids involved in 
"steady state" and "induced" autoreactivity to CD1d, and whether they are the 
same lipids, are also unresolved questions (figure 4).  
The GSL iGb3 was first suggested to be involved in the autoreactivity of type 
I NKT cells [110]. However, recent studies have shown conflicting results 
and whether the autoreactivity of type I NKT cells involves recognition of 
iGb3 is not clarified [113]. Despite this, GSLs seem to possess efficient 
stimulatory capacity for NKT cells. Since we found that physiological 
isoforms of sulfatide, produced during normal conditions in cells, activate a 
set of type II NKT cells, we hypothesized that the natural autoreactivity of 
the sulfatide reactive type II NKT cells was dependent on sulfatide. We found 
that when using splenocytes from mice lacking CST (see figure 5), the 
enzyme required to catalyze the addition of a sulfate group of GalCer to form 
sulfatide, we observed no alteration in the autoreactivity of XV19 cells 
(figure 6A-B, paper I). This demonstrated that the natural autoreactivity of 
NKT cells (called "steady state" autoreactivity in figure 4) is not dependent 
on sulfatide.  
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Knowing that the autoreactivity of XV19 cells does not require sulfatide we 
speculated that the novel stimulatory self-lipids that we identified for XV19 
cells, GlcCer and GalCer, may instead be involved. When using APCs 
deficient in glycosylsynthase (GCS, see figure 5), and thereby lacking GlcCer 
and all downstream GSLs, we found that GlcCer synthesis was not required 
for the autoreactivity of XV19 cells, excluding GlcCer and a range of 
different complex GSLs in the induction of natural autoreactivity of the 
XV19 cells (figure 6A, paper II). From our experiments we could therefore 
exclude sulfatide and the majority of other GSLs, however, GalCer may still 
be responsible for autoreactivity of XV19 cells. We therefore used APCs 
deficient in sphingosine long-chain base subunit 1 (LCB1, see figure 5), 
having a dramatic deficiency in sphingomyelin and all GSLs, but we detected 
no alteration in autoreactivity of XV19 cells when we compared mutant and 
wild type cells (figure 6B, paper II). This suggests that neither GalCer, nor 
any other GSL were necessary for the natural autoreactivity of XV19 NKT 
cells. As mentioned earlier, similar findings have been published regarding 
the natural autoreactivity of type I NKT cells.  
However, studies have shown that GSL synthesis is altered during bacterial 
infections [228], opening the possibility that GSLs could be involved in the 
increased activation of NKT cells by activated DCs. CpG oligonucleotides 
stimulating TLR9 on DCs induced production of charged GSLs that mediated 
type I NKT cell stimulation in the presence of type I interferons [229]. 
Further, TLR ligand activation of human APCs has been shown to modulate 
lipid biosynthesis resulting in increased activation of type I NKT cells to 
secrete IFN-γ [84]. The activation was dependent on both CD1d and soluble 
factors such as IL-12. Another study demonstrates that infections with 
microbes inhibit the action of α-GalA (see figure 5), which is the rate 
limiting enzyme for iGb3 turnover [85], leading to accumulation of self-
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exclude sulfatide and the majority of other GSLs, however, GalCer may still 
be responsible for autoreactivity of XV19 cells. We therefore used APCs 
deficient in sphingosine long-chain base subunit 1 (LCB1, see figure 5), 
having a dramatic deficiency in sphingomyelin and all GSLs, but we detected 
no alteration in autoreactivity of XV19 cells when we compared mutant and 
wild type cells (figure 6B, paper II). This suggests that neither GalCer, nor 
any other GSL were necessary for the natural autoreactivity of XV19 NKT 
cells. As mentioned earlier, similar findings have been published regarding 
the natural autoreactivity of type I NKT cells.  
However, studies have shown that GSL synthesis is altered during bacterial 
infections [228], opening the possibility that GSLs could be involved in the 
increased activation of NKT cells by activated DCs. CpG oligonucleotides 
stimulating TLR9 on DCs induced production of charged GSLs that mediated 
type I NKT cell stimulation in the presence of type I interferons [229]. 
Further, TLR ligand activation of human APCs has been shown to modulate 
lipid biosynthesis resulting in increased activation of type I NKT cells to 
secrete IFN-γ [84]. The activation was dependent on both CD1d and soluble 
factors such as IL-12. Another study demonstrates that infections with 
microbes inhibit the action of α-GalA (see figure 5), which is the rate 
limiting enzyme for iGb3 turnover [85], leading to accumulation of self-
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lipids such as iGb3 in lysosomes of APCs, which further induces vigorous 
activation of type I NKT cells. Also, it was proposed that during steady state, 
iGb3 is constantly degraded by that action of α-GalA. Further, this 
demonstrates that the pool of GSLs in DCs is altered after TLR triggering, 
which leads to increased activation of type I NKT cells. Whether the altered 
representation of GSLs in activated APCs influences the autoreactivity of 
type II NKT cells is not known, however, we have observed increased 
autoreactivity of XV19 cells to LPS-stimulated DCs (figure 10), supporting 
this concept. Thus, it is possible that GSLs, including sulfatide, GlcCer and 
GalCer, may be involved in induced autoreactivity of type II NKT cells 
represented by XV19 cells. 
Figure 10. Increased 
autoreactivity of XV19 cells to 
LPS activated APCs. FLT3L 
derived bone marrow dendritic 
cells (BMDC) were cultured with 
or without (w/o) 1 µg/ml LPS 
over night, before co-culture with 
XV19 cells over night. IL-2 
produced by XV19 cells was 
analyzed by ELISA.  
An alternative model to explain 
autoreactivity of type I NKT cells was put forward by Gapin and coworkers, 
suggesting that it can arise from the direct contact between CD1d and the 
type I NKT TCR [230]. They demonstrated that the presence of unique 
sequences within the hypervariable CDR3β loop can greatly influence type I 
NKT TCR affinity for CD1d presenting self antigens by direct interaction 
with CD1d, [230-233]. This would result in that a broad range of CD1d 
associated self antigens would allow autoreactivity as long as they are not 
interrupting the germline encoded recognition of the CD1d by type I NKT 
TCR. However, for sulfatide reactive type II NKT cells, non-germline 
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sequences seem to dominate the interaction with CD1d presenting self 
antigens, suggesting that this hypothesis might not be generally applicable for 
type II NKT cells.  
Immunomodulation with sulfatide to 
ameliorate disease development 
The effect of sulfatide treatment on type I 
diabetes development (Paper III) 
Sulfatide autoantibodies in type I diabetes prone non-
obese diabetic (NOD) mice 
The increase of sulfatide reactive cells in MS and EAE [30, 163] suggests 
that sulfatide is released during the destruction of the myelin sheath in CNS 
and evokes an immune response. Sulfatide is also present in pancreatic β-
cells, which is the target for destruction during T1D, suggesting that sulfatide 
may be presented to immune cells in a stimulatory manner also in this 
autoimmune disease. In support of this, it has been shown that human 
patients with T1D, but not healthy individuals, have autoantibodies against 
sulfatide in serum [234]. In paper III, our aim was to evaluate whether 
sulfatide induces an immune response in the NOD mouse model for T1D, 
such as the production of autoantibodies and stimulation of sulfatide reactive 
type II NKT cells. We also sought to determine whether the administration of 
sulfatide to NOD mice would suppress the development of T1D. The results 
show that the majority of NOD mice, like non diabetic C57BL/6 mice, only 
have low or background levels of sulfatide autoantibodies, (figure 1A, paper 
III). However, we observed that approximately 25% of NOD mice 
demonstrated increased serum reactivity to sulfatide indicating that 
autoantibodies against sulfatide may arise during T1D pathogenesis, as found 
in humans. However, comparing NOD mice newly diagnosed with T1D and 
healthy NOD mice we did not observe a significant difference, suggesting 
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iGb3 is constantly degraded by that action of α-GalA. Further, this 
demonstrates that the pool of GSLs in DCs is altered after TLR triggering, 
which leads to increased activation of type I NKT cells. Whether the altered 
representation of GSLs in activated APCs influences the autoreactivity of 
type II NKT cells is not known, however, we have observed increased 
autoreactivity of XV19 cells to LPS-stimulated DCs (figure 10), supporting 
this concept. Thus, it is possible that GSLs, including sulfatide, GlcCer and 
GalCer, may be involved in induced autoreactivity of type II NKT cells 
represented by XV19 cells. 
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type I NKT TCR [230]. They demonstrated that the presence of unique 
sequences within the hypervariable CDR3β loop can greatly influence type I 
NKT TCR affinity for CD1d presenting self antigens by direct interaction 
with CD1d, [230-233]. This would result in that a broad range of CD1d 
associated self antigens would allow autoreactivity as long as they are not 
interrupting the germline encoded recognition of the CD1d by type I NKT 
TCR. However, for sulfatide reactive type II NKT cells, non-germline 
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sequences seem to dominate the interaction with CD1d presenting self 
antigens, suggesting that this hypothesis might not be generally applicable for 
type II NKT cells.  
Immunomodulation with sulfatide to 
ameliorate disease development 
The effect of sulfatide treatment on type I 
diabetes development (Paper III) 
Sulfatide autoantibodies in type I diabetes prone non-
obese diabetic (NOD) mice 
The increase of sulfatide reactive cells in MS and EAE [30, 163] suggests 
that sulfatide is released during the destruction of the myelin sheath in CNS 
and evokes an immune response. Sulfatide is also present in pancreatic β-
cells, which is the target for destruction during T1D, suggesting that sulfatide 
may be presented to immune cells in a stimulatory manner also in this 
autoimmune disease. In support of this, it has been shown that human 
patients with T1D, but not healthy individuals, have autoantibodies against 
sulfatide in serum [234]. In paper III, our aim was to evaluate whether 
sulfatide induces an immune response in the NOD mouse model for T1D, 
such as the production of autoantibodies and stimulation of sulfatide reactive 
type II NKT cells. We also sought to determine whether the administration of 
sulfatide to NOD mice would suppress the development of T1D. The results 
show that the majority of NOD mice, like non diabetic C57BL/6 mice, only 
have low or background levels of sulfatide autoantibodies, (figure 1A, paper 
III). However, we observed that approximately 25% of NOD mice 
demonstrated increased serum reactivity to sulfatide indicating that 
autoantibodies against sulfatide may arise during T1D pathogenesis, as found 
in humans. However, comparing NOD mice newly diagnosed with T1D and 
healthy NOD mice we did not observe a significant difference, suggesting 
Results and discussion 
58 
that the increased levels of autoantibodies in a few individual NOD mice 
were independent of clinical manifestations of T1D (Figure 1B, paper III), 
unlike the human situation.  
Previously, it has been shown that old Jα18-/- mice, lacking type I NKT cells, 
on the non autoimmune C57BL/6 genetic background, have increased 
concentrations of autoantibodies in serum [160], similar to the situation in 
systemic lupus erythematosus (SLE). Further, the production of 
autoantibodies towards an increased load of apoptotic cells in the circulation 
was regulated by type I NKT cells in a CD1d dependent manner [161]. This 
suggests that NKT cells are able to regulate the production of autoantibodies 
in mice. Therefore we investigated whether a lack of NKT cells would reveal 
an increased propensity for production of sulfatide autoantibodies in NOD 
mice, however, CD1d-deficient NOD mice lacking all NKT cells did not 
show elevated levels of antibody reactivity to sulfatide (figure 1C, paper III).  
The production of autoantibodies against self-structures such as self-lipids 
expressed by apoptotic cells can be induced even in non-autoimmune mouse 
strains by repeated injection of apoptotic cells [161, 235]. However, injection 
of native sulfatide according to the protocol for induction of autoantibodies 
towards apoptotic cells [161], did not evoke antibody reactivity towards 
sulfatide in autoimmune prone NOD mice nor in healthy C57BL/6 mice 
(figure 2, paper III).   
The immunomodulatory effect of sulfatide treatment in 
T1D prone NOD mice 
We have previously shown that lyso-sulfatide, as well as C24:1 sulfatide, was 
more stimulatory for the type II NKT cell hybridoma XV19 than native 
sulfatide (figure 3, paper I). Therefore we speculated that C24:1 sulfatide 
may be a good candidate for activation of type II NKT cells in vivo. 
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However, even though lyso-sulfatide induced high stimulation of XV19 cells, 
low stimulation of primary cells has been observed (unpublished data), 
suggesting that lyso-sulfatide may not be the optimal choice for CD1d-
dependent immunomodulation to ameliorate disease in NOD mice. When 
testing spleen cells derived from C57BL/6 mice and non diabetic NOD mice 
we found that C24:1 sulfatide gave rise to somewhat increased stimulation 
compared to native sulfatide (figure 3A, paper III). In addition, an increased 
proliferative response was observed by NOD cells compared to cells from 
C57BL/6 mice, suggesting that C24:1 sulfatide is a good candidate for 
sulfatide treatment of NOD mice.   
Several studies using the type I NKT cell ligand α-GalCer have demonstrated 
a protective effect on T1D progression in NOD mice, when administered at 
different time points [236]. Further, native sulfatide has previously been 
shown to modulate autoimmune diseases, infections and tumor immunity [30, 
165, 237, 238], suggesting that sulfatide administration is able to regulate 
immunity in a range of different immune settings. We selected a treatment 
protocol, which was used successfully with α-GalCer and its analogs in NOD 
mice [236]. Hence we injected native sulfatide i.p. twice a week during three 
weeks starting with five or eight week old NOD mice. At the age of five 
weeks, infiltrates of autoagressive T cells start to appear in the pancreas 
[239], indicating T1D initiation, albeit without clinical manifestation. 
Injecting sulfatide from this early time point did not influence the progression 
of disease (figure 4A, paper III). In addition, when administering sulfatide to 
eight week old mice, a time point when NOD mice normally have 
considerable infiltration in the pancreas also failed to influence the disease 
progression (figure 4B, paper III). Thus, we did not observe reduced T1D 
development in NOD mice after sulfatide administration at different time 
points using the present protocol. However, a comprehensive review has 
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that the increased levels of autoantibodies in a few individual NOD mice 
were independent of clinical manifestations of T1D (Figure 1B, paper III), 
unlike the human situation.  
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on the non autoimmune C57BL/6 genetic background, have increased 
concentrations of autoantibodies in serum [160], similar to the situation in 
systemic lupus erythematosus (SLE). Further, the production of 
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suggests that NKT cells are able to regulate the production of autoantibodies 
in mice. Therefore we investigated whether a lack of NKT cells would reveal 
an increased propensity for production of sulfatide autoantibodies in NOD 
mice, however, CD1d-deficient NOD mice lacking all NKT cells did not 
show elevated levels of antibody reactivity to sulfatide (figure 1C, paper III).  
The production of autoantibodies against self-structures such as self-lipids 
expressed by apoptotic cells can be induced even in non-autoimmune mouse 
strains by repeated injection of apoptotic cells [161, 235]. However, injection 
of native sulfatide according to the protocol for induction of autoantibodies 
towards apoptotic cells [161], did not evoke antibody reactivity towards 
sulfatide in autoimmune prone NOD mice nor in healthy C57BL/6 mice 
(figure 2, paper III).   
The immunomodulatory effect of sulfatide treatment in 
T1D prone NOD mice 
We have previously shown that lyso-sulfatide, as well as C24:1 sulfatide, was 
more stimulatory for the type II NKT cell hybridoma XV19 than native 
sulfatide (figure 3, paper I). Therefore we speculated that C24:1 sulfatide 
may be a good candidate for activation of type II NKT cells in vivo. 
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However, even though lyso-sulfatide induced high stimulation of XV19 cells, 
low stimulation of primary cells has been observed (unpublished data), 
suggesting that lyso-sulfatide may not be the optimal choice for CD1d-
dependent immunomodulation to ameliorate disease in NOD mice. When 
testing spleen cells derived from C57BL/6 mice and non diabetic NOD mice 
we found that C24:1 sulfatide gave rise to somewhat increased stimulation 
compared to native sulfatide (figure 3A, paper III). In addition, an increased 
proliferative response was observed by NOD cells compared to cells from 
C57BL/6 mice, suggesting that C24:1 sulfatide is a good candidate for 
sulfatide treatment of NOD mice.   
Several studies using the type I NKT cell ligand α-GalCer have demonstrated 
a protective effect on T1D progression in NOD mice, when administered at 
different time points [236]. Further, native sulfatide has previously been 
shown to modulate autoimmune diseases, infections and tumor immunity [30, 
165, 237, 238], suggesting that sulfatide administration is able to regulate 
immunity in a range of different immune settings. We selected a treatment 
protocol, which was used successfully with α-GalCer and its analogs in NOD 
mice [236]. Hence we injected native sulfatide i.p. twice a week during three 
weeks starting with five or eight week old NOD mice. At the age of five 
weeks, infiltrates of autoagressive T cells start to appear in the pancreas 
[239], indicating T1D initiation, albeit without clinical manifestation. 
Injecting sulfatide from this early time point did not influence the progression 
of disease (figure 4A, paper III). In addition, when administering sulfatide to 
eight week old mice, a time point when NOD mice normally have 
considerable infiltration in the pancreas also failed to influence the disease 
progression (figure 4B, paper III). Thus, we did not observe reduced T1D 
development in NOD mice after sulfatide administration at different time 
points using the present protocol. However, a comprehensive review has 
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demonstrated the complexity of modulating T1D in NOD mice [240]. The 
timing of distinct treatments to achieve optimal protection of T1D varies 
extensively with the particular treatment. Therefore it is possible that the lack 
of effect by sulfatide in our hands may be due to a sub-optimal administration 
protocol, including an inappropriate age of treated mice. At this time, 
Subramanian and colleagues published that native sulfatide, administered i. p. 
once a week for a three week period to twelve week old NOD mice 
significantly reduced spontaneous development of T1D in NOD mice [241], 
suggesting a role for sulfatide reactive type II NKT cells in modulating T1D 
progression in NOD mice. However, when we used the same treatment 
protocol, native as well as the highly stimulatory sulfatide isoform C24:1 
failed to reduce the T1D incidence (figure 11). Therefore, at this time, it is 
unclear to what extent sulfatide treatment is able to reproducibly modulate 
T1D in NOD mice, and further investigations are required to resolve this 
issue.  
 
Figure 11. Sulfatide did not 
reduce T1D incidence when 
administered to 12 week old 
NOD mice. 25 nmol C24:1 or 
native sulfatide were 
administered i. p. to NOD mice 
once a week for a three week 
period starting at twelve weeks 
of age.  
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The effect of sulfatide treatment in S. aureus 
infection (Paper IV) 
NKT cells did not influence the course of S. aureus 
induced sepsis 
Due to the fact that NKT cells rapidly and robustly produce a range of 
different cytokines [74], such as IFN-γ and other pro-inflammatory cytokines, 
we speculate that NKT cells can play a role in the dysregulated immune 
response during S. aureus induced sepsis. In the generalized Shwartzman 
reaction, an experimental model for sepsis in which a lethal shock syndrome 
is induced by two consecutive injections of LPS [191-193], type I NKT cells 
have a pathogenic role. It was demonstrated that mice lacking type I NKT 
cells had significantly increased survival and lower levels of serum IFN-γ and 
TNF-α, suggesting that type I NKT cells promote an excessive pro-
inflammatory response with increased lethality in this endotoxic shock model 
[242].  In paper IV, we investigated whether NKT cells play a role in S. 
aureus induced sepsis in a mouse model developed to more closely represent 
the human life threatening sepsis condition caused by systemic infection by 
S. aureus [212] [213]. 
We first investigated whether NKT cells (see figure 12A-B) were activated 
during S. aureus sepsis.  
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extensively with the particular treatment. Therefore it is possible that the lack 
of effect by sulfatide in our hands may be due to a sub-optimal administration 
protocol, including an inappropriate age of treated mice. At this time, 
Subramanian and colleagues published that native sulfatide, administered i. p. 
once a week for a three week period to twelve week old NOD mice 
significantly reduced spontaneous development of T1D in NOD mice [241], 
suggesting a role for sulfatide reactive type II NKT cells in modulating T1D 
progression in NOD mice. However, when we used the same treatment 
protocol, native as well as the highly stimulatory sulfatide isoform C24:1 
failed to reduce the T1D incidence (figure 11). Therefore, at this time, it is 
unclear to what extent sulfatide treatment is able to reproducibly modulate 
T1D in NOD mice, and further investigations are required to resolve this 
issue.  
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The effect of sulfatide treatment in S. aureus 
infection (Paper IV) 
NKT cells did not influence the course of S. aureus 
induced sepsis 
Due to the fact that NKT cells rapidly and robustly produce a range of 
different cytokines [74], such as IFN-γ and other pro-inflammatory cytokines, 
we speculate that NKT cells can play a role in the dysregulated immune 
response during S. aureus induced sepsis. In the generalized Shwartzman 
reaction, an experimental model for sepsis in which a lethal shock syndrome 
is induced by two consecutive injections of LPS [191-193], type I NKT cells 
have a pathogenic role. It was demonstrated that mice lacking type I NKT 
cells had significantly increased survival and lower levels of serum IFN-γ and 
TNF-α, suggesting that type I NKT cells promote an excessive pro-
inflammatory response with increased lethality in this endotoxic shock model 
[242].  In paper IV, we investigated whether NKT cells play a role in S. 
aureus induced sepsis in a mouse model developed to more closely represent 
the human life threatening sepsis condition caused by systemic infection by 
S. aureus [212] [213]. 
We first investigated whether NKT cells (see figure 12A-B) were activated 
during S. aureus sepsis.  
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Figure 12. Activated type I NKT cells accumulate in spleen, three days post S. aureus 
infection. (A) Live, B220-TCRβ+NK1.1+ were gated for further analysis of (B) α-GalCer 
(PBS57) tetramer negative and positive cells. (C) Absolut numbers of type I NKT cells in 
spleen (D) Mean fluorescence intensity of CD69 on splenic type I NKT cells. 
 
We could demonstrate that the numbers of type I NKT cells (figure 12C) as 
well as the α-GalCer-negative, NK1.1+TCRβ+ cells, most likely containing a 
large fraction of type II NKT cells, were increased in spleen and liver three 
days post infection. Further, these cells demonstrated an increased expression 
of the activation marker CD69, suggesting that NKT cells become activated 
and expand in spleen and liver during the course of S. aureus infection 
(figure 12D). However, we observed no effect on the severity of sepsis in 
mice lacking type I NKT cells (Jα18-/-), nor in mice deficient in all NKT cells 
(CD1d-/-) (figure 2A-B, paper IV), suggesting that even though NKT cells are 
activated by the infection, they do not influence the survival of S. aureus 
infected mice.  
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Sulfatide attenuates experimental S. aureus sepsis 
through type II NKT cells 
In the Shwartzman reaction, activation of type I NKT cells by administration 
of α-GalCer could in fact replace the priming dose of LPS demonstrating the 
early pathological effect induced by type I NKT cells [243]. In terms of 
sulfatide, it has been shown to inhibit HIV replication in mice [166], 
suggesting that sulfatide, through its activation of sulfatide reactive type II 
NKT cells can modulate the immune response to infections. Therefore, we 
investigated the immunomodulatory role of sulfatide in S. aureus induced 
sepsis and were able to show that sulfatide, administered one hour before and 
three days post inoculation of S. aureus, significantly improved the survival 
rate of infected mice (figure 3A-B, paper IV). The protective effect induced 
by sulfatide was observed both in moderate and severe sepsis, demonstrating 
the effectiveness of sulfatide treatment. One dose of sulfatide on day three 
post infection did not mediate protection (figure 3C, paper IV), 
demonstrating lack of therapeutic effect of this single dose of sulfatide. 
However, the positive effect of two administrations of sulfatide encourages 
further studies to optimize the timing of the primary and secondary sulfatide 
dose to achieve a therapeutic effect by sulfatide in S. aureus sepsis. Further, 
the amelioration by sulfatide treatment of S. aureus sepsis required CD1d, 
but was lost in Jα18-/- mice (figure 4, paper IV). This suggests that significant 
protection was mediated by type II NKT cells, and independent of type I 
NKT cells, in this model.  
Mice inoculated with S. aureus and treated with sulfatide demonstrated 
similar bacterial counts in blood, liver and kidneys three days post infection 
(figure 5A, paper IV). However, the pro-inflammatory cytokine burst induced 
by S. aureus infection was decreased after sulfatide administration. Already 
at day one, serum IL-6 levels were significantly reduced. The reduction of 
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Sulfatide attenuates experimental S. aureus sepsis 
through type II NKT cells 
In the Shwartzman reaction, activation of type I NKT cells by administration 
of α-GalCer could in fact replace the priming dose of LPS demonstrating the 
early pathological effect induced by type I NKT cells [243]. In terms of 
sulfatide, it has been shown to inhibit HIV replication in mice [166], 
suggesting that sulfatide, through its activation of sulfatide reactive type II 
NKT cells can modulate the immune response to infections. Therefore, we 
investigated the immunomodulatory role of sulfatide in S. aureus induced 
sepsis and were able to show that sulfatide, administered one hour before and 
three days post inoculation of S. aureus, significantly improved the survival 
rate of infected mice (figure 3A-B, paper IV). The protective effect induced 
by sulfatide was observed both in moderate and severe sepsis, demonstrating 
the effectiveness of sulfatide treatment. One dose of sulfatide on day three 
post infection did not mediate protection (figure 3C, paper IV), 
demonstrating lack of therapeutic effect of this single dose of sulfatide. 
However, the positive effect of two administrations of sulfatide encourages 
further studies to optimize the timing of the primary and secondary sulfatide 
dose to achieve a therapeutic effect by sulfatide in S. aureus sepsis. Further, 
the amelioration by sulfatide treatment of S. aureus sepsis required CD1d, 
but was lost in Jα18-/- mice (figure 4, paper IV). This suggests that significant 
protection was mediated by type II NKT cells, and independent of type I 
NKT cells, in this model.  
Mice inoculated with S. aureus and treated with sulfatide demonstrated 
similar bacterial counts in blood, liver and kidneys three days post infection 
(figure 5A, paper IV). However, the pro-inflammatory cytokine burst induced 
by S. aureus infection was decreased after sulfatide administration. Already 
at day one, serum IL-6 levels were significantly reduced. The reduction of 
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IL-6 was more pronounced day three post infection, when a decrease in TNF-
α was also observed (figure 5B-C, paper IV). This demonstrates an anti 
inflammatory effect of sulfatide at early time points. In addition, sulfatide 
significantly increased platelet counts, suggesting that sulfatide might 
dampen the disseminated intravascular coagulation in S. aureus sepsis (figure 
6A, paper IV). Notably, the pro-inflammatory burst was reduced by sulfatide 
treatment, yet the bacterial count was similar in treated and untreated mice, 
indicating that sulfatide treatment limited adverse effects of inflammation, 
albeit without diminshing the control of bacterial growth, which is promising 
for future development of putative clinical applications.   
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CONCLUDING REMARKS 
The naturally activated steady state phenotype is a hallmark of NKT cells and 
a consequence of their unique developmental program in the thymus, which 
involves selection by self-lipids. As a result, NKT cells rapidly exert their 
effector functions upon activation and are able to regulate the immune system 
in several immune settings, such as autoimmunity and infections. Knowing 
how NKT cells are activated is necessary for understanding their 
immunoregulatory ability. As for today, most information concerns the type I 
NKT cells, due to the fact that efficient reagents identifying type I NKT cells 
are available for these cells but not type II NKT cells. Importantly, studies 
have shown that type I and type II NKT cells are phenotypicly and 
functionally different from each other, which emphasizes the importance of 
gaining more information of the type II NKT cells. Notably, data so far 
suggest that humans, in contrast to mice, have an increased size of the diverse 
(type II), CD1d restricted T cells compared to invariant type I NKT cells.  
In this thesis we demonstrate that type II NKT cells are activated by the 
GSLs sulfatide, GlcCer and GalCer, which are all abundant GSLs in 
mammalians. However, the autoreactivity of the type II NKT cell hybridoma 
XV19 was not dependent on GSLs, suggesting that self-lipids mediating 
steady state autoreactivity of type II NKT cells are non-GSLs. Despite the 
fact that the autoreactivity of type II NKT cells is independent of GSLs, one 
can speculate that these stimulatory GSLs might be involved in induced 
peripheral activation. Also, the fact that sulfatide is abundant in tissues such 
as pancreas and CNS, which is the target for self destruction during 
autoimmune type I diabetes and MS, indicates that sulfatide may activate 
type II NKT cells during the destruction phase of these autoimmune diseases, 
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CONCLUDING REMARKS 
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significantly protects mice from developing severe sepsis, induced by S. 
aureus infection. The protective effect induced by sulfatide in S. aureus 
sepsis was mediated by type II NKT cells. This suggests that induced 
activation of type II NKT cells by administration of the GSL sulfatide 
provided potent immomodulatory effects by these cells.  
Altogether this thesis has expanded the knowledge on the activation of type II 
NKT cells and their immunomodulatory ability. The finding that the GSLs, 
sulfatide, GlcCer and GalCer induce efficient activation of type II NKT cells 
suggests a potential for effectively activate this potent immunomodulating 
type II NKT cell subset in different immune settings.  
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